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A B S T R A C T
Background
Mepolizumab is a humanmonoclonal antibody against interleukin-5 (IL-5), themain cytokine involved in the activation of eosinophils,
which in turn causes airway inflammation. Recent studies have suggested these agents may have a role in reducing exacerbations and
improving health-related quality of life (HRQoL). There are no recommendations for the use of mepolizumab in adults or children in
the recent update of the BTS/SIGN guidelines (BTS/SIGN 2014).
Objectives
To compare the effects of mepolizumab with placebo on exacerbations and HRQoL in adults and children with chronic asthma.
Search methods
We searched the Cochrane Airways Group Register (CAGR) of trials, clinical trial registries, manufacturers’ websites and the reference
lists of included studies. Searches were conducted in November 2013 and updated in November 2014.
Selection criteria
We included randomised controlled trials comparing mepolizumab versus placebo in adults and children with asthma.
Data collection and analysis
Two authors independently extracted data and analysed outcomes using a random-effects model. We used standard methods expected
by The Cochrane Collaboration.
Main results
Eight studies on 1707 participants met the inclusion criteria. Only two studies included children (over 12 years of age), but they did not
report separate findings for the adolescents. Seven studies involved intravenous mepolizumab alone; one included a subcutaneous arm.
There was heterogeneity in the severity and clinical pattern of asthma among the participants in the eight studies, varying from mild
to moderate atopic asthma, to persistent asthma and eosinophilic asthma with recurrent exacerbations. Selection bias was a concern in
several of the studies included in this review.
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Four trials compared intravenous mepolizumab to placebo in relation toHRQoL. Two studies measured scores from the AsthmaQuality
of Life Questionnaire (AQLQ), which showed a non-significant difference between mepolizumab and placebo (mean difference (MD)
0.21, 95% confidence interval (CI)− 0.01 to 0.44; participants = 682), in the direction favouring mepolizumab. The third study used
the St. George’s Respiratory Questionnaire (SGRQ) and found a significant difference between mepolizumab and placebo (MD 6.40,
95% CI 3.15 to 9.65; participants = 576), which indicated a clinically important benefit favouring mepolizumab. A fourth study noted
that there was no significant difference but did not provide any data. The two studies in people with eosinophilic asthma showed a
reduction in clinically significant exacerbation rates (Risk Ratio 0.52, 95% CI 0.43 to 0.64; participants = 690). However, an analysis
of four studies that were not confined to people with eosinophilic asthma indicated considerable heterogeneity and no significant
difference in people with one or more exacerbations betweenmepolizumab and placebo using a random-effects model (Risk Ratio 0.67,
95% CI 0.34 to 1.31; participants = 468; I2 = 59%).The analysis of serious adverse events indicated a significant difference favouring
mepolizumab (Risk ratio 0.49, 95% CI 0.30 to 0.80; participants = 1441; studies = 5; I2 = 0%). It was not possible to combine the
results for adverse events, and we deemed the quality of this evidence to be low.
A single study compared subcutaneousmepolizumab toplacebo in 385 adultswith severe eosinophilic asthma and found an improvement
in HRQoL scores and a reduction in asthma exacerbations, including exacerbations requiring admission to hospital.
Authors’ conclusions
It is not possible to draw firm conclusions from this review with respect to the role of mepolizumab in patients with asthma. Our
confidence in the results of this review are limited by the fact that the intravenous route is not currently licensed for mepolizumab, and
the evidence for the currently licenced subcutaneous route is limited to a single study in participants with severe eosinophilic asthma.
The currently available studies provide evidence that mepolizumab can lead to an improvement in health-related quality of life scores
and reduce asthma exacerbations in people with severe eosinophilic asthma.
Further research is needed to clarify which subgroups of patients with asthma could potentially benefit from this treatment. Dosage,
ideal dosing regimens and duration of treatment need to be clarified, as the studies included in this review differed in their protocols.
There are no studies reporting results from children, so we cannot comment on treatment for this age group. At the present time, larger
studies using licenced treatment regimens are required to establish the role of mepolizumab in the treatment of severe asthma.
P L A I N L A N G U A G E S U M M A R Y
Mepolizumab as opposed to placebo for asthma
Review question
We considered in this review whether taking mepolizumab is better than a placebo for people with asthma.
Background
Asthma is an inflammatory lung condition characterised by the narrowing of the airways, breathlessness, a tight chest and reduced
quality of life. By the year 2025, there may be up to 400 million people with asthma worldwide. Mepolizumab is one treatment that
may help to reduce the symptoms.
Study characteristics
Eight studies compared mepolizumab treatment to a placebo in 1707 patients with asthma. Six studies only included adults. We
summarised the results as they relate to quality of life, occurrence of asthma attacks needing hospital admission and side effects of
mepolizumab.
Key results
We found that patients with severe asthma who had high levels of eosinophils (inflammatory cells in the blood stream) benefited from
taking mepolizumab through improved quality of life and reduced asthma attacks. There was no benefit in terms of lung function. We
have avoided making recommendations because we think that further research is needed to clarify aspects such as dosage and length of
treatment as well as which patients might benefit the most.
2Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
IV mepolizumab compared to placebo for asthma
Patient or population: adults with asthma of varying degrees of severity
Settings: community
Intervention: intravenous (IV) mepolizumab
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo IV mepolizumab
Change in HRQoL as-
sessed with AQLQ.
Scale from 1 to 7 (higher
is better)
Follow-up: 52 weeks
The mean change in
HRQoL ranged from 0.18
to 0.71 units
The mean change in
HRQoL in the interven-
tion group was 0.21 units
more (0.01 fewer to 0.44
more)
- 682
(2 RCTs)
⊕⊕©©
lowa,b
Trial participants had se-
vere eosinophilic asthma
Change in HRQoL as-
sessed with SGRQ.
Scale from: 0 to 100
(lower is better)
Follow-up: 32 weeks
The mean change in
HRQoL was − 9.0 units
The mean change in
HRQoL in the intervention
group was 6.4 units lower
(3.15 lower to 9.65 lower)
- 382
(1 RCT)
⊕⊕⊕©
moderatea
Trial participants had se-
vere eosinophilic asthma
Rate of clinically signifi-
cant exacerbations - 75
mg mepolizumab versus
placebo
Follow-up: range 32 to 52
weeks
The mean rate of clinically
significant exacerbations
on placebo was 1 per pa-
tient per yearc
The mean rate of clinically
significant exacerbations
in the intervention group
was 0.48 less per patient
per year (0.57 less to 0.
46 less)
Rate ratio 0.52 (0.43 to 0.
64)
690
(2 studies)
⊕⊕⊕©
moderatea
Trial participants had se-
vere eosinophilic asthma
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Rate of clinically signifi-
cant exacerbations - 250
mg mepolizumab versus
placebo
Follow-up: 52 weeks
The mean rate of clinically
significant exacerbations
on placebo was 0.43 per
patient per year
The mean rate of clinically
significant exacerbations
in the intervention group
was 0.17 less per patient
per year (0.08 less to 0.
23 less)
Rate ratio 0.61 (0.46 to 0.
81)
307
(1 study)
⊕⊕⊕©
moderatea
Trial participants had se-
vere eosinophilic asthma
Rate of clinically signifi-
cant exacerbations - 750
mg mepolizumab versus
placebo
Follow-up: 52 weeks
The mean rate of clinically
significant exacerbations
on placebo was 0.43 per
patient per year
The mean rate of clinically
significant exacerbations
in the intervention group
was 0.22 less per patient
per year (0.17 less to 0.
25 less)
Rate ratio 0.48 (0.36 to 0.
64)
311
(1 study)
⊕⊕⊕©
moderatea
Trial participants had se-
vere eosinophilic asthma
People with one or more
exacerbations
Follow-up: 20 to 50
weeks
264 per 1000 177 per 1000
(90 to 345)
Risk ratio 0.67
(0.34 to 1.31)
467
(4 studies)
⊕⊕©©
lowa,d
Variety of asthma severity
in the trials
Serious adverse events
Follow-up: 20 to 52
weeks
82 per 1000 40 per 1000
(24 to 65)
Risk ratio 0.49
(0.30 to 0.80)
1441
(5 studies)
⊕⊕⊕©
moderatea
Variety of asthma severity
in the trials
*The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison
group and the relative effect of the intervention (and its 95% CI).
AQLQ: Asthma Quality of Life Questionnaire; CI: Confidence interval; HRQoL: health-related quality of life; IV: intravenous; RCT: randomised controlled trial; SGRQ: St George’s Respiratory
Questionnaire.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aThe intravenous route is not currently licenced for mepolizumab; one point deducted for indirectness.
bThe mean difference is less than the clinical minimally important difference (0.5 units), and no responder analysis is available; one point
deducted.
cPlacebo exacerbation rate per patient per year is the rounded mean of rate in the placebo arm of the two studies (0.43 and 1.75).4
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dWide confidence interval increases the uncertainty of this outcome; one point deducted.
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B A C K G R O U N D
Description of the condition
A recent global estimate of the number of people currently suffer-
ing from asthma is in the region of 300 million, and it is expected
that by 2025 the number will increase to 400 million (WHO
2007). The subsequent burden of disease is likely to continue to
impose additional pressures on patients, their families and health-
care systems (Masoli 2004). The increased incidence in morbidity
has been associatedwith suboptimal delivery of care, including un-
der-treatment with corticosteroids and a limited awareness of the
condition amongst patients (Gibson 1993; Kandane-Rathayake
2009).
In the USA, the number of people with asthma increased from
20 million in 2001 to 25 million in 2009 (CDC 2011). Preva-
lence rates are slightly higher among children (10%) than among
adults (8%) (CDC 2011; CDC2012), with considerable variation
among different ethnic groups. Between 2008 and 2010, asthma
prevalence rates in the USA were 14.1% among multiracial indi-
viduals, 11.2% among blacks, 9.4% among Alaska Natives, 9.4%
among other Native Americans, 7.7% among whites and 5.2%
among those of Asian descent (CDC 2011). Globally, the preva-
lence ofwheezing symptoms in children varies geographically, with
the UK having the highest recorded prevalence of current wheez-
ing at 32.3% and Ethiopia the lowest at 1.7% (Patel 2008).
For many people, asthma has an important impact on quality of
life (Clayton 2005) and on financial considerations (Wu 2007).
In the USA, approximately 10 million people experience asthma
exacerbations each year (Krishnan 2006), and in the UK, over
65,000 hospital admissions for asthma were recorded in 2005 and
2006 (NHS 2011).
In recent years, clinical guidelines have been produced for the
management of asthma at national (e.g. BTS/SIGN 2014; NIH
2007) and international (GINA 2012) levels. Several risk factors
for asthma have been identified, including triggers such as aller-
gens, chemical irritants and tobacco smoke, but asthma-related
mortality and morbidity remain a major health concern (Braman
2006). On the other hand, the condition can also be controlled
and health-related quality of life (HRQoL) maintained for con-
siderable periods (WHO 2011).
Description of the intervention
One of the core pathological features of asthma is considered to be
eosinophilic infiltration of the bronchial mucosa, which triggers an
inflammatory response. Mepolizumab is a humanised monoclonal
antibody against interleukin-5 (IL-5) that has been shown to in-
hibit eosinophilic airway inflammation. A number of studies have
been conducted in young adults (> 12 years old) and adults with
recurrent severe asthma exacerbations and signs of eosinophilic in-
flammation (Haldar 2009; Nair 2009; Pavord 2012). The results
of these studies suggest that inhibiting eosinophilic inflammation
by monoclonal antibodies may be associated with a reduced risk
of acute exacerbations of asthma and a reduction in eosinophil
count.
How the intervention might work
Proteins secreted by eosinophils cause damage to the epithelium,
initiating vasodilatation, smoothmuscle contraction and increased
mucous secretion,which in turn is associatedwith increased airway
hyperresponsiveness, asthma symptoms and airway narrowing (
Liu 2013).
Mepolizumab is a keymonoclonal antibody inhibiting IL-5,which
is the main cytokine involved in eosinophil activation and recruit-
ment. This intervention might work by preventing the initiation
of the inflammatory response. Mepolizumab is administered in-
travenously as either a one-off dose of 2.5 to 10 mg/kg or monthly
doses of 75 mg, 250 mg or 750 mg given for a period ranging from
16 to 52 weeks. Mepolizumab can also be given subcutaneously.
Why it is important to do this review
In a recently publishedmeta-analysis of seven randomised placebo-
controlled trials on 1131 adults, mepolizumab was shown to re-
duce the risk of exacerbations and improve quality of life in people
with eosinophilic asthma, but did not lead to a significant im-
provement in lung function (Liu 2013).
It is important to do this review so that the evidence presented
and the judgements made in Liu 2013 are available and placed in
context within The Cochrane Library. Our review will also set the
stage for future updates as more evidence becomes available.
O B J E C T I V E S
To compare the effects of mepolizumab with placebo on exacer-
bations and HRQoL in adults and children with chronic asthma.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs). We included
studies reported as full text, those published as abstracts only and
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unpublished data. Included trials were a minimum of 16 weeks in
duration.
Types of participants
We included both adults and children with a diagnosis of asthma.
We focused on collating data from people who have been reported
as having eosinophilic asthma to analyse these individuals as a
subgroup. We examined individual articles in order to determine
how this group should be defined.
Individuals with congential heart disease and respiratory comor-
bidities such as cystic fibrosis were excluded, as were current smok-
ers.
Types of interventions
We included trials comparing mepolizumab with placebo. We
planned to include the following cointerventions provided they
were not part of the randomised treatment: leukotriene antag-
onists, inhaled bronchodilators (including long-acting beta2-ag-
onists), systemic and inhaled steroids, oral aminophylline and
macrolide antibiotics.
Studies that initiated a reduction in standard asthma management
as part of the protocol were excluded. Nair 2009 included a reduc-
tion in the dose of prednisolone in the second phase of the trial.
Therefore, only phase one of this trial was included as patients
remained on their standard asthma treatment during this four-
week period.
Types of outcome measures
Primary outcomes
1. HRQoL (as measured by a validated questionnaire)
2. Asthma exacerbation as defined by a hospital admission or
treatment with a course of oral corticosteroids
3. Serious adverse events
Secondary outcomes
1. Measures of lung function: forced expiratory flow in one
second (FEV1), peak expiratory flow rate (PEFR)
2. Asthma symptoms
3. Adverse events/side effects
4. Eosinophil counts in peripheral blood, sputum or
bronchioalveolar lavage fluid
Reporting one or more of the outcomes listed here in the trial was
not an inclusion criterion for the review.
Search methods for identification of studies
Electronic searches
We identified trials from the Cochrane Airways Group Spe-
cialised Register (CAGR), which is maintained by the Trials
Search Co-ordinator for the Group. The Register contains trial
reports identified through systematic searches of bibliographic
databases, including the Cochrane Central Register of Controlled
Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED
and PsycINFO. We also handsearched respiratory journals and
meeting abstracts (please see Appendix 1 for further details). We
searched all records in the CAGR using the search strategy in
Appendix 2.
We also conducted a search of
ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health
Organization (WHO) trials portal (www.who.int/ictrp/en/).
We searched all databases from their inception to the present and
imposed no restriction on language of publication. The search was
first conducted in November 2013 and was updated in November
2014.
Searching other resources
We checked the bibliographies of all primary studies and review
articles for additional references. We searched relevant manufac-
turers’ websites for trial information.
We searched for errata and retractions relevant to the included
studies published in full text on PubMed (www.ncbi.nlm.nih.gov/
pubmed) and planned to report the date this was done within the
review if this was an issue.
Data collection and analysis
Selection of studies
Two review authors (NW, CP) independently screened titles and
abstracts of all the potential studies identified in the search and
coded them as ’retrieve’ (eligible or potentially eligible/unclear) or
’do not retrieve’. We retrieved the full-text study reports/publica-
tions, and two review authors (NW, CP) independently screened
the full text and identified studies for inclusion, identifying and
recording reasons for excluding the ineligible studies. We planned
to resolve any disagreement through discussion or, if required, by
consulting a third author (SJM); however, this was not necessary.
We identified and excluded duplicates and collated multiple re-
ports of the same study so that each study rather than each report
was the unit of interest in the review. We recorded the selection
process in sufficient detail to complete a PRISMA flow diagram
and a ’Characteristics of excluded studies’ table.
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Data extraction and management
We used a data collection form to record study characteristics and
outcome data that had been piloted on at least one study in the
review. Two review authors (LB, NW) extracted the following
study characteristics from included studies.
1. Methods: study design, total duration of study, details of
any run-in period, number of study centres and location, study
setting, withdrawals and date of study.
2. Participants: number, mean age, age range, gender, severity
of condition, diagnostic criteria, baseline lung function, smoking
history, inclusion criteria and exclusion criteria.
3. Interventions: intervention, comparator, concomitant
medications and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial and notable conflicts of interest of
trial authors.
Two review authors (LB, NW) independently extracted outcome
data from included studies. We noted in the ’Characteristics of
included studies’ table if outcome data were not reported in a
usable way. We planned to resolve disagreements by consensus
or by involving a third author (CP), but this was not necessary.
One review author (KD) transferred data into Review Manager
(RevMan). We double-checked that data were entered correctly
by comparing the data presented in the systematic review with the
study reports. A second review author (SJM) spot-checked study
characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (LB, NW) independently assessed risk of bias
for each study using the criteria outlined in theCochraneHandbook
for Systematic Reviews of Interventions (Higgins 2011).We planned
to resolve any disagreements by discussion or by involving another
author (SJM), but this was not necessary. We assessed the risk of
bias according to the domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We graded each potential source of bias as high, low or unclear,
and provided a quotation from the study report together with
a justification for this judgement in the ’Risk of bias’ table. We
summarised the risk of bias judgements across different studies
for each of the domains listed. We considered blinding separately
for different key outcomes where necessary (e.g. for an unblinded
outcome assessment, risk of bias for all-cause mortality may be
very different than that for a patient-reported pain scale). Where
information on risk of bias related to unpublished data or corre-
spondence with a trialist, we noted this in the ’Risk of bias’ table.
When considering treatment effects, we took into account the risk
of bias for the studies that contributed to that outcome.
We conducted the review according to this published protocol and
have reported any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We analysed dichotomous data as risk ratios and rate ratios and
continuous data as mean differences or standardised mean differ-
ences, which are presented with 95% confidence intervals. We en-
tered data presented on a scale with a consistent direction of effect.
However, on one occasion we had to use the risk ratio as one study
had reported this (Haldar 2009).
Wehave undertakenmeta-analyses onlywhere thiswasmeaningful
(i.e. if the treatments, participants and underlying clinical question
were sufficiently similar for pooling to make sense).
Where multiple trial arms were reported in a single trial (Flood-
Page 2007; Pavord 2012), we combined the relevant arms (750
mg, 250 mg, 75 mg in Pavord 2012 and 750 mg, 250 mg in
Flood-Page 2007) when appropriate.
In future updates of this review, wewill narratively describe skewed
data reported as medians and interquartile ranges. Wheremultiple
trial arms are reported in a single trial, we will include only the
relevant arms. If two comparisons (e.g. drug A versus placebo and
drug B versus placebo) are combined in the same meta-analysis,
we will halve the control group to avoid double-counting.
Unit of analysis issues
No cross-over studies or cluster randomised trials were identified
for inclusion in this version of the review. If cross-over trials are
identified in the future, data from a paired analysis will be sought
from the trial report or authors in order to appropriately include
data in the review using the inverse variance method. If cluster
randomised trials are identified in the future, then analyses will
be at the level of the individual while allowing for the clustering
in the data by using the intracluster correlation coefficient. If this
is not reported in the trial, then it will be imputed from similar
studies.
Dealing with missing data
Although unnecessary for this version of the review, we may con-
tact investigators or study sponsors for future versions in order
to verify key study characteristics and obtain missing numerical
outcome data where possible (e.g. when a study is identified as an
abstract only). Where this is not possible, and the missing data
are thought to introduce serious bias, we will explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis.
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Assessment of heterogeneity
Statistical heterogeneity between studies was assessed visually by
inspection of the forest plots and using the Chi2 test (a P value <
0.10 was considered significant due to the low power of the test).
The I2 statistic was also calculated; this describes the percentage of
the variability in effect estimates that is due to heterogeneity rather
than sampling error (chance). Values of I2 range from0%to100%,
with 0% representing no heterogeneity and 100% representing
considerable heterogeneity.
For this review, heterogeneity as reported using the I2 statistic was
defined as follows.
• 0% to 40%: heterogeneity might not be important.
• 30% to 60%: may represent moderate heterogeneity.
• 50% to 90%: may represent substantial heterogeneity.
• 75% to 100%: considerable heterogeneity.
Assessment of reporting biases
If we are able to pool more than 10 trials for future versions, we
will create and examine a funnel plot to explore possible small
study biases and publication bias.
Data synthesis
In view of the considerable clinical heterogeneity between the in-
cluded studies, we used a random-effects model.
Data on outcomes were combined at 6 months and 12 months.
Where data for other time points were reported, these were also
described.
Subgroup analysis and investigation of heterogeneity
Provided sufficient studies were included, we planned to carry out
subgroup analyses according to:
1. age (0 to 5 years, 6 to 16 years, 17 years and older);
2. eosinophilic individuals versus non-eosinophilic
individuals; and
3. dose of intervention (posthoc subgroup identified);
using the outcomes:
1. HRQoL; and
2. asthma symptoms.
If more studies are included in the future, we will use the formal
test for subgroup interactions in RevMan.
Sensitivity analysis
We planned to carry out the following sensitivity analyses if suffi-
cient studies were included.
1. Excluding studies with an overall high risk of bias.
2. Excluding cross-over trials and cluster randomised trials.
Summary of findings table
We created ’Summary of findings’ tables using the following out-
comes.
1. HRQoL.
2. Asthma exacerbation as defined by a hospital admission or
treatment with a course of oral corticosteroids.
3. Serious adverse events.
We used the five GRADE considerations (study limitations, con-
sistency of effect, imprecision, indirectness and publication bias)
to assess the quality of the body of evidence as it relates to the
studies that contribute data to the meta-analyses for the prespeci-
fied outcomes. We used methods and recommendations described
in Section 8.5 and Chapter 12 of the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011) using GRADEpro
software. We have justified all decisions to downgrade or upgrade
the quality of studies using footnotes, and we have made com-
ments to aid the reader’s understanding of the review where nec-
essary.
R E S U L T S
Description of studies
Results of the search
We identified 154 records in our literature searches: 129 in
database searches in November 2013 and a further 25 in Novem-
ber 2014 (Figure 1). Eight studies met our inclusion crite-
ria (’Characteristics of included studies’ table), and two others
were included in the ongoing studies category (’Characteristics
of ongoing studies’ table). The eight included studies had 25
records: one for Buttner 2003; seven for Flood-Page 2003, one
for Flood-Page 2007, four for Haldar 2009, one for Leckie 2000;
five for Nair 2009; two for Ortega 2014 and four for Pavord
2012. The remaining 127 records were excluded for various rea-
sons (’Characteristics of excluded studies’ table).
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Figure 1. Study flow diagram
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Included studies
We included eight studies (’Characteristics of included studies’
table), involving 1707 total participants distributed as follows:
Buttner 2003, 19; Flood-Page 2003, 24; Flood-Page 2007, 362;
Haldar 2009, 61; Leckie 2000, 24; Nair 2009, 20; Ortega 2014,
576 Pavord 2012, 621. Table 1 compares the design, numbers, in-
terventions and patient groups in the included trials. The severity
of asthma among participants varied from mild atopic asthma to
persistent eosinophilic asthma with recurrent exacerbations. The
mepolizumab was administered exclusively through intravenous
route in seven of the studies, with dosage varying from 2.5 mg/kg
or 10 mg/kg, or 75 mg, 250 mg and 750 mg with different dosing
regimens over a range of treatment periods. Only one study had a
subcutaneous (SC) arm, with a dose of 100 mg (Ortega 2014).
Excluded studies
We excluded 127 records from the review. Of these, 119 (94%)
were excluded because mepolizumab had not been included in
the study, 4 (3%) were excluded because they did not include a
placebo arm, another 2 (2%) were excluded because the focus was
on steroid reduction, 1 (1%) was non-randomised, and the re-
maining study (1%) was conducted on healthy participants with-
out a diagnosis of asthma (’Characteristics of excluded studies’ ta-
ble).
Risk of bias in included studies
Details of our risk of bias assessments are available in the
’Characteristics of included studies’ table, and a summary of our
assessment can be seen in Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
We deemed only three studies (Nair 2009; Pavord 2012; Ortega
2014) to be at low risk of bias for both random sequence generation
and allocation concealment. We judged Haldar 2009 to be at low
risk of bias for random sequence generation, but its biaswith regard
to allocation concealment was unclear. The risk of bias for the
remaining four studies (Buttner 2003; Flood-Page 2003; Flood-
Page 2007; Leckie 2000) was unclear for both random sequence
generation and allocation concealment (Figure 3).
Blinding
With regard to performance bias and detection bias, we deter-
mined that all eight studies were at low risk of bias (Figure 3).
Incomplete outcome data
In terms of attrition bias, we considered seven of the studies to
be at low risk of bias, while the risk of bias in Buttner 2003 was
unclear (Figure 3).
Selective reporting
One study noted that there was no significant difference in
HRQoL but did not provide any data (Flood-Page 2007), so we
considered it to be at high risk of bias. We deemed all other stud-
ies to be at low risk of bias as there was no apparent evidence of
selective reporting.
Effects of interventions
See: Summary of findings for themain comparison Intravenous
mepolizumab compared to placebo for asthma; Summary of
findings 2 Subcutaneous mepolizumab compared to placebo for
asthma
Primary outcomes
HRQoL (as measured by a validated questionnaire)
Three studies (participants = 1044) measured quality of life using
the Asthma Quality of Life Questionnaire (AQLQ) (Flood-Page
2007;Haldar 2009; Pavord 2012).One study noted that there was
no significant difference but did not provide any data (Flood-Page
2007).
Intravenous mepolizumab versus placebo
Pavord 2012 reported data at 52 weeks for three different dose
groups of Intravenous (IV) mepolizumab (75 mg, 250 mg, 750
mg),whichwe combined andpresented as one group.Haldar 2009
reported data at 50 weeks. Combining the two studies, Analysis
1.1 showed a non-significant difference between IV mepolizumab
and placebo (MD 0.21, 95% CI − 0.01 to 0.44; participants =
682), favouring IV mepolizumab. Our confidence in this result is
low, as the mean difference is less the clinical minimally important
difference of 0.5 units, and no responder analysis is reported (
Summary of findings for the main comparison).
Ortega 2014 measured quality of life using the St. George’s Respi-
ratory Questionnaire (SGRQ) and found a significant difference
favouring IV mepolizumab over the placebo (MD 6.40, 95% CI
3.15 to 9.65; participants = 382; Analysis 1.2).We only havemod-
erate confidence in this result, as IV delivery is not currently a
licenced route of administration for mepolizumab (Summary of
findings for the main comparison).
Subcutaneous mepolizumab versus placebo
Ortega 2014 measured quality of life using the St. George’s Respi-
ratory Questionnaire (SGRQ) and found a significant difference
between subcutaneous (SC) mepolizumab and placebo, in favour
of mepolizumab (MD − 7.00, 95% CI − 10.19 to − 3.81; par-
ticipants = 385; Analysis 2.1). We have moderate confidence in
this result from a single study (Summary of findings 2).
Asthma exacerbation as defined by a hospital admission or
treatment with a course of oral corticosteroids
Six studies (participants = 1664) reported on asthma exacerbations
(Flood-Page 2003; Flood-Page 2007; Haldar 2009; Nair 2009;
Pavord 2012; Ortega 2014). Increase in oral corticosteroids is in-
cluded in the definition of exacerbation for three studies (Haldar
2009; Ortega 2014; Pavord 2012). Two studies did not include
an increase in oral corticosteroids in the definition of exacerbation
(Flood-Page 2007; Nair 2009), while one study did not provide a
definition of exacerbation (Flood-Page 2003).
IV Mepolizumab versus placebo
Four studies ( Flood-Page 2003; Flood-Page 2007; Haldar 2009;
Nair 2009) reported the number of patients experiencing an ex-
acerbation. Analysis 1.6, which used a random-effects model, did
not show a significant difference between IV mepolizumab and
placebo (Risk Ratio 0.67, 95%CI 0.34 to 1.31; participants = 468
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I2 = 59%).Our confidence in this result is low due to the wide con-
fidence intervals (Summary of findings for the main comparison).
Pavord 2012 reported the rate ratio of exacerbations for each of
the three different dose groups of IV mepolizumab compared to
placebo. Ortega 2014 reported the percentage reduction in the
rate ratio for clinically significant exacerbations for 75 mg IV
mepolizumab compared to placebo. We combined the results for
groups taking the 75 mg dose from these studies, both of which
included participants with severe eosinophilic asthma.
Analysis 1.3 shows similar results for the rate of clinically signifi-
cant exacerbations, which include a course of oral steroids, emer-
gency department (ED) visit or admission. For the 75mg dose, the
rate of EDvisits or hospital admissions for people onmepolizumab
was half that of the placebo group (rate ratio 0.52, 95% CI 0.43
to 0.64; participants = 690; studies = 2). For the 250 mg dose, the
result was similar (rate ratio 0.61, 95% CI 0.46 to 0.81; partici-
pants = 307; studies = 1) and also for the 750 mg dose (rate ratio
0.48, 95% CI 0.36 to 0.64; participants = 311; studies = 1). Our
confidence in this result is moderate, as IV delivery is not currently
a licenced delivery route for mepolizumab (Summary of findings
for the main comparison).
Analysis 1.4 shows the rate ratio for the combined results of these
two studies in terms of exacerbations requiring hospital admission,
and there is not a significant difference for the 75mgmepolizumab
dose (rate ratio 0.61, 95% CI 0.33 to 1.13; participants = 690;
studies = 2). The 750 mg IV mepolizumab group compared to
placebo showed a reduction in the risk of being admitted to hos-
pital (rate ratio 0.37, 95% CI 0.16 to 0.86; participants = 311;
studies = 1). The 250 mg dose did not show a statistically sig-
nificant reduction (rate ratio 0.65, 95% CI 0.31 to 1.37; partic-
ipants = 307; studies = 1), but the difference between doses was
not significant (test for subgroup differences: Chi2 = 1.14, degree
of freedom (df ) = 2 (P = 0.57), I2 = 0%).
Analysis 1.5 shows the combined results on exacerbations requir-
ing a visit to the ED or hospital admission. For the 75 mg dose,
there was a significant reduction in the exacerbation rate for this
outcome (rate ratio 0.52, 95%CI 0.31 to 0.87; participants = 690;
studies = 2), and although the reduction in rate was similar for the
other doses, it did not reach statistical significance (250 mg dose:
rate ratio 0.58, 95% CI 0.30 to 1.12; participants = 307; stud-
ies = 1; and 750 mg dose: rate ratio 0.52, 95% CI 0.27 to 1.02;
participants = 311; studies = 1). Again there was no significant
difference between the results according to dose (test for subgroup
differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 = 0%).
SC Mepolizumab versus placebo
Ortega 2014 also found a reduction in the rate of all of the above
types of exacerbations favouring SC mepolizumab in comparison
to placebo. Analysis 2.2 shows the results for hospital admission
(rate ratio 0.31, 95%CI 0.11 to 0.91; participants = 385; studies =
1). Analysis 2.3 shows the reduction in either ED visits or hospital
admission (rate ratio 0.39, 95% CI 0.18 to 0.83; participants =
385; studies = 1). Analysis 2.4 shows the reduction in clinically
significant exacerbations (rate ratio 0.47, 95% CI 0.35 to 0.63;
participants = 385; studies = 1). We have moderate confidence in
these results from a single study (Summary of findings 2).
Serious adverse events
Five studies (participants = 1640) reported information on serious
adverse events.
Nair 2009 stated that there were no serious adverse events, while
Pavord 2012 reported that the overall frequency of serious adverse
events was similar across treatment groups and that no serious life-
threatening anaphylactic reactions were observed; however, three
patients in the IV mepolizumab groups died during the study for
reasons that the physician investigator judged to be unrelated to
the treatment.
Flood-Page 2007 reported nine serious adverse events: four in pa-
tients receiving placebo (vertigo, bladder carcinoma, unintended
pregnancy and asthma exacerbation), three in patients receiving
IV mepolizumab 250 mg (hydrocephalus/cerebrovascular disor-
der, constipation and gastrointestinal disturbance), and two in pa-
tients receiving IV mepolizumab 750 mg (asthma exacerbation).
None of these serious adverse events was considered to be related
to the study medication, and there were no significant differences
between the treatment groups.
Haldar 2009 reported that hospitalisation for asthma was a se-
rious adverse effect for 10% (3/29) of participants in the IV
mepolizumab arm and 34% (11/32) in the placebo arm.
Ortega 2014 reported that the incidence of serious adverse events
(including asthma-related events) was 7% in the intravenous
mepolizumab group, 8% in the subcutaneous mepolizumab
group, and 14% in the placebo group.
Analysis 1.7 indicated that there was a significant difference be-
tween IV mepolizumab versus placebo (Risk Ratio 0.49, 95% CI
0.30 to 0.80; participants = 1441; studies = 5; I2 = 0%), favouring
IV mepolizumab. Our confidence in this result is moderate, as
IV delivery is not currently a licenced route of administration for
mepolizumab (Summary of findings for the main comparison).
Secondary outcomes
Measures of lung function: forced expiratory flow in one
second (FEV1), peak expiratory flow rate (PEFR)
Seven studies (participants = 1688) report on lung function
(Flood-Page 2003; Flood-Page 2007; Haldar 2009; Leckie 2000;
Nair 2009; Pavord 2012; Ortega 2014).
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IV Mepolizumab versus placebo
Flood-Page 2003 reported no difference between IVmepolizumab
and placebo for median FEV1 and median PEFR at 12 weeks
(Table 2).
Flood-Page 2007 reportedmean change fromplacebo for FEV1 (L)
and PEFR L/min at weeks 12 and 20. Analysis 1.8 indicates there
was no significant difference in FEV1 between IV mepolizumab
and placebo at week 20. Analysis 1.9 shows a significant difference
for IV mepolizumab 250 mg compared to placebo (MD 13.49;
95% CI 0.71 to 26.27), but not for the 750 mg compared to
placebo group (MD 3.42, 95% CI − 9.40 to 16.24). However,
the test for subgroup difference was not significant (Chi2 = 1.19,
df = 1 (P = 0.280), I2 = 15.9%).
Haldar 2009 and Nair 2009 reported no significant difference
in post-bronchodilator FEV1 (L) between IV mepolizumab and
placebo at one year and six weeks, respectively (Analysis 1.10).
Nair 2009 also reported no difference between IV mepolizumab
and placebo for percentage predicted FEV1 after bronchodilation
(Analysis 1.11).
Pavord 2012 found no significant difference between any dose of
IV mepolizumab and placebo in pre-bronchodilator FEV1 (mL)
at one year (Analysis 1.13).
Leckie 2000 reports no significant difference between IV
mepolizumab and placebo in late asthmatic reaction (maximum
percentage fall in FEV1) (Analysis 1.14).
Ortega2014 reported a statistically significant difference favouring
IV mepolizumab for both pre- and post-bronchodilator FEV1
(MD 0.10 L ; 95% CI 0.01 to 0.19); (MD 0.15 L, 95% CI 0.05
to 0.24), (Analysis 1.10; Analysis 1.12).
SC Mepolizumab versus placebo
Ortega2014 reported a statistically significant difference favouring
SC mepolizumab for both pre- and post-bronchodilator FEV1
(MD 0.10, 95% CI 0.02 to 0.18; participants = 385; studies = 1
and MD 0.14, 95% CI 0.04 to 0.23; respectively) (Analysis 2.5;
Analysis 2.6;).
Asthma symptoms
Five studies (participants = 1640) measured asthma symptoms
(Flood-Page 2007; Haldar 2009; Nair 2009; Pavord 2012; Ortega
2014).
IV Mepolizumab versus placebo
Flood-Page 2007 reported results at 20 weeks using the asthma
summary symptom score. Nair 2009 reported data at 4 weeks
using a symptom score, a cough score and the Juniper Asthma
Cough Questionnaire (JACQ) score. Haldar 2009 reported data
at one year using the visual analogue scale symptom score and a
modified Juniper Asthma Control Score. Pavord 2012 reported
data using the asthma control questionnaire at one year. Ortega
2014 reported data at 32weeks using the five-itemAsthmaControl
Questionnaire (ACQ-5).
There were no significant differences between IV mepolizumab
at 250 mg or 750 mg and placebo using an asthma symptom
score or the JACQ, but there was a significant difference between
75 mg and placebo (MD − 0.30, 95% CI − 0.55 to − 0.04;
participants = 690; studies = 2; Analysis 1.15), although test for
subgroup difference was again non-significant (Chi2 = 0.81, df =
2 (P = 0.67), I2 = 0%).
SC Mepolizumab versus placebo
There was also a statistically significant improvement in symptoms
on SC mepolizumab compared to placebo (MD − 0.44, 95%
CI − 0.64 to − 0.24; participants = 385; studies = 1); Analysis
2.7). However, there was no responder analysis, and this mean
difference is less than the minimal clinically important difference
of − 0.5 units.
Adverse events/side effects
Six studies (participants = 1664) reported adverse events (Flood-
Page 2003; Flood-Page 2007; Haldar 2009; Nair 2009; Pavord
2012; Ortega 2014).
Flood-Page 2003 reported that all of the 24 volunteers completed
the study without reporting adverse events.
Flood-Page 2007 reported that there were no significant differ-
ences between the treatment groups for any adverse events re-
ported. The most common adverse events (at least 5% of partici-
pants in any treatment group) were upper respiratory tract infec-
tion, asthma, headache, rhinitis, bronchitis, sinusitis, viral infec-
tion, injury, back pain, nausea and pharyngitis.
Haldar 2009 reported that one patient withdrew due to rash after
mepolizumab infusion.
Nair 2009 reported that one patient in the IVmepolizumab group
withdrew because of increased shortness of breath, thought to be
due to heart failure. One patient in the placebo group died six
months after the study because of sudden cardiac arrest; one patient
in the IV mepolizumab group reported aches and tiredness when
prednisolone was reduced, and one patient in the placebo group
had hypoadrenalism when prednisolone was reduced.
Pavord 2012 found that the most frequently reported adverse
events were headache (27 (17%) individuals given placebo, 32
(21%) given 75 mg IV mepolizumab, 32 (21%) given 250 mg IV
mepolizumab, and 32 (21%) given 750 mg IV mepolizumab) and
nasopharyngitis (24 (15%), 34 (22%), 33 (22%), and 29 (19%)
for the four groups, respectively). The most frequently reported
drug-related adverse event was infusion-related reaction (e.g. non-
allergic reactions), which was reported by 10 (6%) patients given
placebo, 8 (5%) given 75mgmepolizumab, 12 (8%) given 250mg
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IV mepolizumab, and 19 (12%) given 750 mg IV mepolizumab.
Hypersensitivity deemed to be possibly related to investigational
product was reported by three patients (2%) given placebo, none
given 75 mg IV mepolizumab, one (< 1%) given 250 mg IV
mepolizumab, and two (1%) given 750 mg IV mepolizumab.
In the Ortega 2014 study, the overall incidence of adverse events
during treatment was similar in the three groups (84% in the IV
mepolizumab group, 78% in the SC mepolizumab group, and
83% in the placebo group). The most frequently reported adverse
events were nasopharyngitis and headache. The incidence of ad-
verse events that were considered by the study investigators to be
related to a study drug was 17% in the IV mepolizumab group,
20% in the SC mepolizumab group, and 16% in the placebo
group. The incidence of injection-site reactions was more frequent
in the SC mepolizumab group (9%) than in the IV mepolizumab
group or the placebo group (3% in each).
Eosinophil counts in peripheral blood, sputum or
bronchioalveolar lavage fluid
All eight studies (participants = 1707) report on eosinophil counts
(Buttner 2003; Flood-Page 2003; Flood-Page 2007; Haldar 2009;
Leckie 2000; Nair 2009; Pavord 2012; Ortega 2014).
Buttner 2003 found that “[a]sthmatic patients received three con-
secutive intravenous infusions of either IV mepolizumab (250 mg
or 750 mg per dose) or placebo at 4-week intervals. Remarkably,
almost a complete disappearance of peripheral blood eosinophils
was observed after the first infusion. Eosinophil counts remained
low or absent until week 24, 12 weeks after the last infusion. In
contrast, there were no significant changes in eosinophil counts in
the placebo group. Themarked fall in peripheral blood eosinophils
was accompanied by a significant decrease in ECP concentrations.
The kinetics of ECP (serum eosinophil cationic protein) levels re-
sembled the eosinophil counts. These qualitative and quantitative
changes were observed in both treatment groups without a signif-
icant difference between the 250 and 750 mg dosage.”
Flood-Page 2003 found that at four weeks after the first dose of
IV mepolizumab, there was a significant decrease in peripheral
blood eosinophil counts in the actively treated group when com-
pared with placebo (P = 0.002). This decrease was maintained
throughout the dosing period and was still evident at the time of
the repeat bronchoscopy and bone marrow aspirate, [at] Week 10
(P = 0.02). There was a median reduction of 100% from base-
line of eosinophils in the actively treated group at Weeks 4 and
10 (interquartile range, 67-100%). A return of blood eosinophil
counts toward baseline was observed at a mean of 9 weeks after the
last dose (range 4-20 weeks, data not shown). IV mepolizumab
produces a 79%median reduction in bronchoalveolar lavage fluid
(BALF) eosinophils (interquartile range, 42-99%) (P = 0.4 when
compared with placebo) (Table 3).
Flood-Page 2007 found a significant reduction in the eosinophil
counts in the 250 mg and 750 mg groups at week 1 (P < 0.001).
Also, 32 patients gave samples at baseline and week 12; 17 had
sputum eosinophils > 3%. There was a significant decrease in both
the 250 mg (P = 0.006) and the 750 mg group (P = 0.004), which
was also significant when compared to placebo.
Haldar 2009 reports a significant difference between IV
mepolizumab and placebo for geometric mean sputum eosinophil
percentage during exacerbation, and a sputum eosinophil count >
3% during exacerbation (% of episodes), Table 4. The study also
reports, “[T]he geometric mean of eosinophil counts in the blood
during the treatment phase, as compared with the baseline value,
was reduced by a factor of 6.6 in the mepolizumab group and by a
factor of 1.1 in the placebo group, with the changes from baseline
differing between the groups by a factor of 6.1 (95% CI, 4.1 to
8.9; P < 0.001).”
Results from Leckie 2000 are presented in Table 5. There was a
significant reduction in blood eosinophils pre-allergen challenge
in the group given mepolizumab 10 mg/kg. Postinhaled allergen,
there was a significant reduction in blood eosinophils in both
groups givenmepolizumab. There was a dose dependent reduction
in sputum eosinophils in both mepolizumab groups. This result
reached statistical significance in the 10 mg/kg group.
Ortega 2014 found a significant decrease in both treatment groups
in blood eosinophil count.
Results from Nair 2009 can be found in Table 6. In phase 1 of
the trial, a single infusion of mepolizumab 750 mg resulted in a
reduction in the number of sputum and blood eosinophils.
Pavord 2012 found that compared with placebo, the ratios of
geometric means at 52 weeks showed that the drug reduced blood
eosinophil counts (ratios of geometricmeans 0.22, 95%CI 0.18 to
0.27) in individuals given 75 mgmepolizumab (P < 0.0001; ratios
of geometricmeans 0.14; 95%CI 0.12 to 0.18), in those given 250
mg mepolizumab, (P < 0.0001; ratios of geometric means 0.12;
95% CI 0.09 to 0.14) and in those given 750 mg mepolizumab,
(P < 0.0001). In the subgroup of 94 participants who had sputum
induction, the drug also caused decreases in sputum eosinophil
counts compared with placebo (ratio 0.68. 95% CI 0.13 to 3.52),
in individuals given 75 mg mepolizumab (P = 0.6429; ratios of
geometric means 0.35, 95% CI 0.08 to 1.52), in those given 250
mg mepolizumab (P = 0.1577; 0.12 95% CI 0.02 to 0.56) and in
those given 750 mg (P = 0.0082).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Subcutaneous mepolizumab compared to placebo for asthma
Patient or population: adults with severe eosinophilic asthma
Settings: community
Intervention: subcutaneous (SC) mepolizumab
Comparison: placebo
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo SC mepolizumab
Change in HRQoL as-
sessed with SGRQ.
Scale from: 0 to 100
(lower is better)
Follow-up: 32 weeks
The mean HRQoL was −
9.0 units
The mean HRQoL - SGRQ
in the intervention group
was 7 units fewer (10.19
fewer to 3.81 fewer)
- 385
(1 RCT)
⊕⊕⊕©
moderatea
Rate of exacerbations re-
quiring admission
Follow-up: 32 weeks
The mean rate of exacer-
bations requiring admis-
sion on placebo was 0.10
per patient per year
The mean rate of exacer-
bations requiring ED visit
or admission in the inter-
vention group was 0.07
less per patient per year
(0.01 less to 0.09 less)
Rate ratio 0.31
(0.11 to 0.91)
385
(1 RCT)
⊕⊕⊕©
moderatea
Rate of exacerbations re-
quiring ED or admission
Follow-up: 32 weeks
The mean rate of ex-
acerbations requiring ED
or admission on placebo
was 0.20 per patient per
year
The mean rate of exac-
erbations requiring ED or
admission in the interven-
tion group was 0.12 less
per patient per year (0.03
less to 0.16 less)
Rate ratio 0.39
(0.18 to 0.83)
385
(1 RCT)
⊕⊕⊕©
moderatea
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Rate of clinically signifi-
cant exacerbations
Follow-up: 32 weeks
The mean rate of clinically
significant exacerbations
on placebo was 1.75 per
patient per year
The mean rate of clinically
significant exacerbations
in the intervention group
was 0.93 less per patient
per year (0.65 less to 1.
14 less)
Rate ratio 0.47
(0.35 to 0.63)
385
(1 RCT)
⊕⊕⊕©
moderatea
Asthma symptoms mea-
sured on Asthma Control
Questionnaire
Scale from: 0 to 6 (lower
is better)b
Follow-up: 32 weeks
The mean change in
asthmasymptomswas−
0.5 units
The mean asthma symp-
toms in the intervention
group was 0.44 units
fewer (0.64 fewer to 0.24
fewer)
- 385
(1 RCT)
⊕⊕⊕©
lowa,c
*The basis for the assumed risk was the event rate in the placebo arm of the single included study. The corresponding risk (and its 95% confidence interval) is based on the assumed risk
in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; ED: emergency department; HRQoL: health-related quality of life; RCT: randomised controlled trial; SC: subcutaneous; SGRQ: St George’s Respiratory Questionnaire.
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
aThis finding is from a single study so we do not know how well this will match further research; one point deducted.
bThe minimal clinically important difference on this scale is 0.5 units.
cThe mean difference is less than the clinical minimally important difference (0.5 units), and no responder analysis is available; one point
deducted.
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D I S C U S S I O N
Summary of main results
Eight studies met our inclusion criteria for this systematic review
(Buttner 2003; Flood-Page 2003; Flood-Page 2007; Haldar 2009;
Leckie 2000; Nair 2009; Pavord 2012; Ortega 2014). Six studies
included adults participants only, while Pavord 2012 and Ortega
2014 included participants aged 12 years and over, with a mean
age of around 50 years and no separate reporting of results in
adolescents. In total, 1707 people participated.
The results suggest that mepolizumab leads to an improvement
in HRQoL and a reduction in asthma exacerbation rates for
people with severe eosinophilic asthma randomised to received
mepolizumab compared to placebo, with no significant increase
in serious adverse events on treatment.
With regard to the secondary outcome measures, mepolizumab
did not lead to a significant increase in measures of lung function
(FEV1 or PEFR). There was no significant difference in asthma
symptoms using an asthma symptom score or the JACQ between
IV mepolizumab at 250 mg or 750 mg and placebo. However,
there was a significant difference between 75 mg IV mepolizumab
and placebo (although a non-significant test for subgroup dif-
ference) and between SC mepolizumab and placebo, in partici-
pants with severe eosinophilic asthma. There were minimal sig-
nificant adverse events related to mepolizumab, but headache and
nasopharyngitis were commonly reported side effects. Due to the
variety of dosing regimens and protocols, direct comparison of
eosinophil counts in peripheral blood, sputum and bronchoalve-
olar fluid was not possible.
Peripheral blood eosinophil counts, sputum eosinophil counts and
eosinophil counts in bronchoalveolar fluid all showed a significant
reduction after treatment with mepolizumab.
There were only two studies that included paediatric patients,
down to the age of 12 years old (Ortega 2014; Pavord 2012), but
there was no separate reporting of results in adolescents, so we
have insufficient evidence to undertake a subgroup analysis based
on age.
Overall completeness and applicability of
evidence
Although the precise definition of asthma exacerbation is subject
to debate, with the consequent variability in reporting, it is never-
theless considered to be one of the core outcomes to bemeasured in
asthma studies (Fuhlbrigge 2012). We found evidence of a reduc-
tion in the rate of clinically significant exacerbations in adults with
severe eosinophilic asthma given IV or SC mepolizumab. Health-
related quality of life (HRQoL) improved with intervention com-
pared to placebo by a mean of seven units in the single study using
SGRQ (Ortega 2014), but the mean change in AQLQ was less
than the minimal clinically important difference and was not ac-
companied by responder analyses. These two primary outcomes
are clinically important outcomes for the individual. Secondary
outcomes of asthma symptoms scores, cough scores, lung function
and airway hyperreactivity were not influenced by mepolizumab.
Most studies examined eosinophils, inflammatory markers and
mediators using a combination of peripheral blood, sputum and
bronchoalveolar lavage and showed reductions in those who re-
ceived mepolizumab. The clinical relevance of this finding to pa-
tients may not be clinically important. There were no studies in
children under 12 and only two studies included children aged
12 years or older (but without disaggregating results for the par-
ticipating adolescents). The asthma population examined in this
review was too heterogeneous to draw any conclusions about the
general asthma population.
Quality of the evidence
Using the GRADE system, we considered the quality of evidence
for IVmepolizumab to be limited, as this is not a licenced delivery
route (so we would regard this as indirect evidence). We felt that
the HRQoL results were of moderate quality, and further research
may have an important effect on the results presented. There was
a risk of reporting bias in the assessment of HRQoL for one paper:
Flood-Page 2007 noted no significant changes in HRQoL but did
not provide any data, thus no data could be included in the meta-
analysis. We are aware of the limitations in some of the studies
and have detailed them in the results section, Figure 2 and Figure
3. We determined that the risk of performance bias and detection
bias based on the blinding processes was low in all eight studies.
We also found that selection bias was low in only three studies
for both random sequence generation and allocation concealment
(Nair 2009; Ortega 2014; Pavord 2012) but unclear in four others
(Buttner 2003; Flood-Page 2003; Flood-Page 2007; Leckie 2000).
Haldar 2009 had a low risk of bias for random sequence gener-
ation, but the risk of bias was unclear with respect to allocation
concealment. Publication bias was not formally assessed through
the construction of a funnel plot due to the small number of in-
cluded studies.However, we performed a thorough search strategy,
including searching conference abstracts and ongoing studies, in
order to identify unpublished studies.
Potential biases in the review process
We acknowledge the potential for publication bias in this review,
as it is possible that we failed to identify unpublished trials that
may have provided positive or negative outcomes, which in turn
could have altered the treatment benefits. However, to the best of
our knowledge, we identified a significant number of trials meet-
ing our inclusion criteria through comprehensive and systematic
database searches. We tried to address any study selection bias by
19Mepolizumab versus placebo for asthma (Review)
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having two review authors who independently evaluated all the
identified studies. We also ensured that the assessment of each trial
was consistently in line with the inclusion criteria.
Agreements and disagreements with other
studies or reviews
Our review follows on from Liu 2013, which also considered the
efficacy of mepolizumab in patients with asthma. The present
review includes one extra study (Ortega 2014), and its findings
are consistent with Liu 2013. Both reviews highlight the need for
further research in this area.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
It is not possible to draw firm conclusions from this review with
respect to the role of mepolizumab versus placebo in patients with
asthma, due partly to the heterogeneity of the studies.
The currently available studies provide evidence thatmepolizumab
leads to an improvement in health-related quality of life scores
and a reduction of asthma exacerbations in people with severe
eosinophilic asthma (Haldar 2009; Nair 2009; Pavord 2012;
Ortega 2014). There was also an improvement in asthma symp-
tom scores in subjects with persistent eosinophilic asthma when
using subcutaneous mepolizumab and 75 mg mepolizumab intra-
venously (Ortega 2014). Mepolizumab did not lead to a signifi-
cant increase in measures of lung function.
Further research is needed to clarify which subgroups of patients
with asthma could potentially benefit from this treatment.Dosage,
ideal dosing regimens and duration of treatment need to be clar-
ified, as the studies included in this review differed in their pro-
tocols. There were only two studies that included children (over
the age of 12), and these do not provide sufficient evidence on
which to base a recommendation for use. At the present time,
larger studies are required to establish the role of mepolizumab in
the treatment of asthma.
Implications for research
There needs to be further research on mepolizumab in children,
with a focus on the core outcomes of exacerbations and HRQoL
but also asthma symptoms and lung function (in children who
can perform respiratory function tests).
In adults, the evidence available so far suggests that there is an
improvement in HRQoL and frequency of acute exacerbations
in participants with severe eosinophilic asthma. However, there
needs to be further research to ascertain the optimum dose and
regimen for mepolizumab therapy, as the studies included in this
review used a wide range of dosing regimens.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Buttner 2003
Methods Randomised, placebo-controlled, parallel-group trial
Participants Reported as: “Seven male and 12 female patients with mild or moderate asthma, aged
20-59 yrs (mean 41 yrs), with duration of disease between 1-32 yrs (mean 11 yrs) were
investigated. For inclusion, FEV1 had to be from 50 to 80% of predicted at baseline,
with a reversibility of at least 12%. None of the patients suffered from
clinical exacerbation, and all patients were on a stable daily dose of up to 1000 mcg
beclomethasone dipropionate or a corresponding dose of other inhaled corticosteroids
for at least 6 weeks prior to the study. As a symptom reliever salbutamol was allowed if
needed.The detailed clinical characterisation of patients revealed no significant difference
between the study groups.”
5 participants allocated to receive mepolizumab 750 mg, 7 to receive mepolizumab 250
mg and 7 to receive placebo
Interventions 1 month run-in period to ensure stable disease
3 intravenous doses of either mepolizumab (750 mg), mepolizumab (250 mg) or placebo
every 4 weeks with a follow-up period of 3 months
Outcomes Peripheral blood leukocytes, qualitative and quantitative distribution of eosinophils and
lymphocyte subpopulations, frequencies of IL-2, -3, -4, -5, -10, -13, interferon-c-pro-
ducing CD4 T-cells and serum eosinophil cationic protein (ECP) levels
Notes 6-month multicentre trial in Germany
Supported in part by SmithKline Beecham, Harlow, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Method of randomisation not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Appears to be unreported
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Buttner 2003 (Continued)
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Flood-Page 2003
Methods 2-centre, double-blind, placebo-controlled, parallel-group study
Participants Reported as: “Twenty-four people withmild asthma, with a FEV1 of 70% ormore of pre-
dicted. Participants were within an 18- to 55-year-old age range. All were atopic (defined
by a positive skin prick test to one or more aeroallergen), and all were well controlled
with short-acting 2-agonists, without corticosteroids or other anti-inflammatory drugs
in the preceding 8 weeks
All participants had a clear history of asthma, demonstrated airway hyperresponsiveness
with a PC20 to histamine of 4.0 mg/mL or less. All were nonsmokers. Eleven participants
received mepolizumab and 13 received placebo.”
• Age: mepolizumab, median 31 years (range 20 to 53); placebo, median 30 years
(range 20 to 52)
• Males: mepolizumab, 9; placebo, 8
• Baseline morning PEFR, L/min: mepolizumab, median 433 (range 358 to 585);
placebo, median 459.5 (range 368 to 490)
• Baseline FEV1, L/s: mepolizumab, median 3.05 (range 2.55 to 4.85); placebo,
median 3.1 (range 1.8 to 5.25)
• Baseline FEV1, % predicted: mepolizumab, median 87.0 (range 71 to 109);
placebo, median 80.0 (range 71 to 106)
Interventions 3 Intravenous doses of either 750 mg of mepolizumab or placebo over 20 weeks (at weeks
0, 4 and 8)
Outcomes Airway eosinophils, bone marrow eosinophils, blood eosinophils, airway hyperrespon-
siveness, FEV1 and PEFR
Notes 20-week study conducted at the Royal Brompton and London Chest Hospitals, London
UK
Supported by GlaxoSmithKline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Method of randomisation not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
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Flood-Page 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk All 24 volunteers completed the study
without reporting adverse events or asthma
exacerbations
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Flood-Page 2007
Methods Multicentre, randomised, double-blind, placebo-controlled trial
Participants Reported as: “Enrolled into the study were nonsmoking participants, aged 18-55 years,
with asthma managed with inhaled corticosteroids (maximum dose of beclomethasone
dipropionate (BDP) or equivalent, 1000 mcg/d). The FEV1 had to be at least 50% and
not more than 80% of the predicted value for age, sex, and height with documented
beta2-agonist reversibility of at least 12% after administration of 180 mcg of albuterol
(salbutamol). The daily symptom score had to be at least 4 (maximum score, 12) during
the 7 days preceding the baseline assessment. The principal exclusion criteria to ensure
asthma stability and safety before dosing were as follows: an absolute FEV1 value mea-
sured at randomisation (visit 3) that had changed by more than 20% from the value
determined at a baseline signs-and-symptoms visit 2 weeks before dosing (visit 2); an
upper respiratory tract infection in the 2 weeks before the first visit; use of oral corti-
costeroids in the 4 weeks before the first visit; or poorly controlled asthma, defined as
hospitalisation or an emergency room visit for the treatment of asthma in the 6 weeks
before the first visit.”
• 116 allocated to receive mepolizumab 750 mg (112 completed), 120 to receive
mepolizumab 250 mg (110 completed) and 126 to receive placebo (119 completed)
• Age (standard deviation (SD)): mepolizumab 750 mg, mean 36.3 years (±10.4),
mepolizumab 250 mg, mean 35.8 years (± 40); placebo, mean 36.8 years (± 10)
• Males: mepolizumab 750 mg, 60; mepolizumab 250 mg, 52; placebo, 48
• Baseline ICS (beclomethasone) dose (mcg/d) (SD): mepolizumab 750 mg, mean
710 (± 381); mepolizumab 250 mg, mean 720 (± 448); placebo, mean 740 (± 486)
• Baseline morning mean PEFR (L/min) (SD): mepolizumab 750 mg, 375.7 (± 88.
8); mepolizumab 250 mg 357.9 (± 90.6); placebo, 359.4 (± 90.4)
• Baseline mean FEV1 (L) (SD): mepolizumab 750 mg, 2.51 (±0.58);
mepolizumab 250 mg, 2.46 (± 0.56); placebo, 2.39 (± 0.59)
• Baseline mean (SD) FEV1, % predicted: mepolizumab 750 mg, 68.3% (± 8.8%);
mepolizumab 250 mg, 68.4% (± 9.6%); placebo, 68.4% (± 8.7%)
• Baseline mean (SD) FEV1 reversibility: mepolizumab 750 mg, 24.5% (± 11.6%);
mepolizumab 250 mg, 24.6% (± 12.1%); placebo, 25.1% (± 11.6%)
Interventions 4-week run-in period to ensure stable disease
3 intravenous doses of mepolizumab (750 mg), mepolizumab (250 mg) or placebo (at
weeks 0, 4 and 8)
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Flood-Page 2007 (Continued)
Outcomes Reported as: “The primary efficacy variable was the change from baseline in domiciliary
morning peak expiratory flow rate (PEFR) recorded at weeks 12 and 20. This was
recorded as the mean PEFR over the 7 days preceding the treatment period (baseline
value) and preceding weeks 12 and 20. The secondary efficacy variables were the changes
from baseline of FEV1, asthma summary symptom scores (the total of the daytime
asthma, nighttime asthma, and morning asthma scores), use of rescue medication such
as albuterol (salbutamol), quality of life scores, asthma exacerbation rates, and eosinophil
counts in blood and sputum.”
Notes 20-week multicentre trial at 55 centres in 5 countries (France, Germany, Netherlands,
the UK, and the USA)
Supported by GlaxoSmithKline.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Method of randomisation not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported as: “Of the 362 patients ran-
domised into the study, a total of 21 pa-
tients (5.8%) were withdrawn. The per-
centage of patients completing the study
was high for all treatment arms. The most
common reason for withdrawal during
the study was adverse experience (n=10;
2.8%). The percentage of patients who
were withdrawn because of adverse experi-
ences was higher among patients receiving
placebo (4.0%) and mepolizumab at 250
mg (3.3%) compared with patients receiv-
ing mepolizumab at 750 mg (0.9%). A to-
tal of 37 patients were randomised to the
induced sputum arm of the study, and 3
patients were subsequently withdrawn.”
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Flood-Page 2007 (Continued)
Selective reporting (reporting bias) High risk No significant difference in HRQoL and
did not provide any data
Haldar 2009
Methods Randomised, double-blind, placebo-controlled, parallel-group trial
Participants Participants had refractory eosinophilic asthma and a history of recurrent severe exacer-
bations
Reported as: “Inclusion criteria were a diagnosis of refractory asthma according to Amer-
ican Thoracic Society criteria, a sputum eosinophil percentage of more than 3% on at
least one occasion in the previous 2 years despite high-dose corticosteroid treatment,
and at least two exacerbations requiring rescue prednisolone treatment in the previous
12 months. Additional criteria for inclusion were stable treatment requirements and an
absence of exacerbations for more than 6 weeks before enrolment in the study. Exclu-
sion criteria were current smoking, serologic evidence of a parasitic infection, a serious
coexisting illness, the possibility of conception, and poor adherence to treatment.”
• Age: mepolixumab, mean 48 (range from 21 to 63); placebo, mean 50 (range
from 24 to 72)
• Males: mepolixumab, 14; placebo, 18
• Baseline mean (SD) FEV1, % predicted after bronchodilator use: mepolizumab,
78.1% (± 20.9%); placebo, 77.6% (± 24.1%)
• Baseline mean (SD) FEV1/FVC ratio: mepolizumab, 72.2% (± 9.6%), placebo,
67.7% (± 13.5%)
• 29 allocated to receive mepolizumab 750 mg, 32 to receive placebo
Interventions Intravenous mepolizumab (750 mg) versus matched placebo (150 mL of 0.9% saline)
at monthly intervals for 1 year
Outcomes Reported as: “[P]rimary outcome measure was the number of severe exacerbations per
subject during the 50-week treatment phase. Secondary outcomes included a change
in asthma symptoms, scores on the Asthma Quality of Life Questionnaire (AQLQ, in
which scores range from 1 to 7, with lower values indicating more severe impairment
and a change of 0.5 unit considered to be clinically important), forced expiratory vol-
ume in 1 second (FEV1) after use of a bronchodilator, airway hyperresponsiveness, and
eosinophil counts in the blood and sputum.”
Notes Single centre trial conducted at Institute for Lung Health, Leicester, UK
Supported by GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported as: “Stratified randomisation
with use of the minimisation method,
which was performed by
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Haldar 2009 (Continued)
an independent clinician. Participants were
randomly assigned with the use of themin-
imisation method to receive 12 infusions
of either 750 mg of mepolizumab delivered
intravenously or matched placebo (150 mL
of 0.9% saline) at monthly intervals be-
tween visits 3 and 14. The criteria used for
minimisation were the frequency of exac-
erbations in the previous 12 months, the
baseline eosinophil count in the sputum
and the number of participants taking oral
corticosteroids.”
Allocation concealment (selection bias) Unclear risk Details not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reported as: “A total of 61 of the 63 par-
ticipants ( one required and operation and
one withdrew consent) who were screened
started treatment and constituted themod-
ified intention-to-treat population. Thirty-
two participants were randomly assigned
to receive placebo. Overall, 94.9% of treat-
ment visits were completed. Participants
who withdrew completed a mean of 4.6
treatment visits (38.3%).”
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
Leckie 2000
Methods Randomised, double-blind, placebo-controlled trial
Participants Participants with mild allergic asthma
Reported as: “24 non-smoking men (mean age 27, range 18-45 years) with mild allergic
asthma (as defined by the
American Thoracic Society) and a history of episodic wheeze and shortness of breath.
The patients were atopic,
as defined by positive skin tests in response to common airborne allergens (Der-
matophagoides pteronyssinus, mixed
grass pollen and cat hair) and were maintained on short-acting inhaled 2-agonist treat-
ment as required. Patients had neither worsening asthma nor a respiratory infection in
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Leckie 2000 (Continued)
the preceding 6 weeks. FEV1 at baseline was at least 70% of the predicted value and
there was a documented airway hyperresponsiveness to histamine, with a provocation
concentration causing a 20% reduction in FEV1 (PC20) < 8 mg/mL. Patients had doc-
umented early and late asthmatic responses (defined as a 15% reduction in FEV1 on at
least three occasions between 4 and 10 h after allergen) to inhaled incremental allergen
challenge between 3 and 6 weeks before the study treatment was given.”
• Mean age (SD): mepolizumab 10 mg/kg, 28.0 years (± 4.3); mepolizumab 2.5
mg/kg, 30.0 (± 8); placebo, 25.6 (± 4.1)
• Males: mepolizumab 10 mg/kg, 8; mepolizumab 2.5 mg/kg, 8; placebo, 8
• Baseline mean (SD) FEV1, % predicted: mepolizumab 10 mg/kg, 82.0% (± 7.
0%); mepolizumab 2.5 mg/kg, 90.3% (± 10.4%); placebo, 93.0% (± 9.6%)
• 8 allocated to receive mepolizumab 10 mg/kg (8 completed), 8 allocated to
receive mepolizumab 2.5 mg/kg (7 completed) and 8 to receive placebo (8 completed)
Interventions Mepolizumab 10 mg/kg versus mepolizumab 2.5 mg/kg versus placebo
Outcomes Blood eosinophils, sputumeosinophils, histamine PC20 (mg/mL), late asthmatic reaction
(maximum % fall in FEV1)
Notes 16 week study conducted at 3 centres: Imperial College London, Southampton Univer-
sity and University of Amsterdam
Supported by SmithKline Beecham, UK
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomisation not reported
Allocation concealment (selection bias) Unclear risk Method of randomisation not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 subject lost to follow-up, all other data
appears to be reported
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
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Nair 2009
Methods Randomised, double-blind, placebo-controlled trial
Participants Inclusion criteria: Adult patients, aged 18 to 70 years, who were followed as outpatients
and who required a minimum dose of prednisone treatment (in addition to high-dose in-
haled steroid treatment) to prevent frequent exacerbations associated with induced spu-
tum eosinophilia. Patients were enrolled if, at screening and baseline visits, they demon-
strated sputum eosinophilia and symptoms. The symptoms could affect activity and
sleep but should not have been severe enough to be of concern to the treating physician.
Both FEV1 (after appropriately withholding bronchodilators before and after inhaled
salbutamol 200 mcg) and methacholine PC20 were measured, but these did not need to
be abnormal since the prednisone was required for the control of eosinophilic bronchitis
and any clinical consequences of this, and because bronchitis can occur without these
features of asthma. On the same doses of corticosteroids for a least one month
Exclusion criteria: pregnancy, breastfeeding or lack of effective contraception in females
of childbearing potential or females who are postmenopausal < 1 year. Baseline predicted
FEV1 before bronchodilator of 40%or less. This lower FEV1 was acceptable since chronic
airflow limitation, secondary to the eosinophilic bronchitis or asthma, is not an exclusion
criterion. Neither is current or ex-cigarette smoking provided that the best FEV1 in
these patients was >60% predicted normal, or the best FEV1/VC ratio was >60% in the
previous two years. Exposure to a relevant seasonal environmental allergen, known to
worsen asthma control, during the study period. Respiratory tract infection in the 4weeks
before the baseline visit. Clinical exacerbation requiring extra prednisone treatment in
the 4 weeks before visit 1. Other cardiac, pulmonary, renal or systemic diseases that in the
investigator’s opinion could interfere with the study results or compromise participants’
safety. Previous participation in any study using anti-monoclonal drug
9 patients were assigned to receive mepolizumab (administered in 5 monthly infusions
of 750 mg each) and 11 patients to receive placebo
• Mean age (SD): mepolizumab, 56.4 years (± 10.9); placebo, 58.2 years (± 7)
• Male: mepolizumab, 4; placebo, 8
• Mean (SD) duration of symptoms: mepolizumab, 13.3 years (± 10.3); placebo,
12.5 years (± 9.5)
• Baseline mean (SD) FEV1 previous minimum (L): mepolizumab, 1.4 (± 0.6);
placebo, 1.6 (± 0.5)
• Baseline mean (SD) FEV1, % predicted: mepolizumab, 48% (± 17); placebo,
52% (± 13%)
Interventions 5 intravenous doses of either mepolizumab (750 mg) or placebo (administered in 5
monthly infusions)
Outcomes Primary outcome:
The prednisone-sparing effect ofmepolizumabversus placebo as indicated by the absolute
and percentage dose reduction possible without a clinical exacerbation (as measured by
the JACQ in patients with asthma or by Likert symptom scores + FEV1 in patients with
eosinophilic bronchitis without asthma).
Secondary outcome measures:
The prednisone-sparing effect of mepolizumab or placebo as indicated by the absolute
and percentage dose reduction possible without a clinical exacerbation, as measured by;
• % sputum eosinophils;
• FEV1 % predicted and methacholine PC20;
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• blood eosinophils;
• amount of rescue salbutamol used;
• time to exacerbation.
Notes 26-week trial at Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and
Department of Medicine, McMaster University, Hamilton, ON, Canada
Supported by an unrestricted educational grant from GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation codes
stratified patients into two groups of 10 ac-
cording to the daily dose of prednisone they
were receiving at the time of enrolment (<
10 mg or ≥ 10 mg). Within each of the
two groups, patients were equally divided
among those receiving mepolizumab and
those receiving placebo.When either group
was filled, no additional patients were re-
cruited for that group
Allocation concealment (selection bias) Low risk Randomisation codes were held by the
pharmacy department, whose members
were unaware of clinical details in the study
groups
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Reported as double blind
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Reported as double blind
Incomplete outcome data (attrition bias)
All outcomes
Low risk Two of the patients were included in the
study in error and were therefore excluded
from some but not all of the analyses before
the randomisation code was broken
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
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Ortega 2014
Methods Randomised, double-blind, double-dummy, phase 3 study
Participants 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflam-
mation despite high doses of inhaled glucocorticoids to one of three study groups
Inclusion criteria:
• Able to give written informed consent prior to participation in the study
• At least 12 years of age at visit 1 with a minimum weight of 45kg
• A well-documented requirement for regular treatment with high dose ICS in the
12 months prior to visit 1, with or without maintenance oral corticosteroids (OCS)
• Current treatment with an additional controller medication, besides ICS, for at
least 3 months, or a documented failure in the past 12 months of an additional
controller medication for at least 3 successive months
• Prior documentation of eosinophilic asthma or high likelihood of eosinophilic
asthma
• At visit 1, a pre-bronchodilator FEV1 < 80% (for participants ≥ 18 years of age),
a pre-bronchodilator FEV1 < 90% or FEV1/FVC ratio < 0.8 (for participants 12 to17
years of age)
• Previously confirmed history of two or more exacerbations requiring treatment
with systemic corticosteroids
• Male or eligible female (females of childbearing potential must commit to
consistent and correct use of an acceptable method of birth control)
• French participants will be included only if affiliated to or a beneficiary of a social
security category
Exclusion criteria:
• Current smokers or former smokers with a smoking history of ≥ 10 pack-years
• Presence of a known pre-existing, clinically important lung condition other than
asthma
• A current malignancy or previous history of malignancy in previous 12 months
• Known, pre-existing, unstable liver disease cirrhosis and known biliary
abnormalities
• Known, pre-existing severe or clinically significant cardiovascular disease
• Known, pre-existing other concurrent clinically significant medical conditions
that are uncontrolled with standard treatment
• Participants with any eosinophilic diseases
• QTc(F)a ≥ 450 ms or QTc(F) ≥ 480 ms
• A history of alcohol/substance abuse
• Known immunodeficiency
• Administration of omalizumab within 130 days of visit 1 or any other
monoclonal antibody to treat inflammatory disease within 5 half-lives of visit 1
• Treatment with an investigational drug within the previous 30 days or 5 terminal
phase half-lives of the drug, whichever is longer
• Allergy/intolerance to a monoclonal antibody or biologic therapy
• Pregnant or breastfeeding
• Known evidence of lack of adherence to controller medications, inability to
follow physician’s recommendations, or both
• Previous participation in any study with mepolizumab and administration of
investigational product (including placebo)
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Ortega 2014 (Continued)
Interventions Mepolizumab in a 75 mg intravenous dose versus mepolizumab in a 100 mg
subcutaneous dose versus placebo every 4 weeks for 32 weeks
Outcomes Primary outcome:
• Number of clinically significant exacerbations of asthma per year
Secondary outcomes:
• Number of clinically significant exacerbations requiring hospitalisation (including
intubation and admittance to an intensive care unit ) or ED visits per year
• Mean change from baseline in clinic pre-bronchodilator FEV1 at week 32
• Mean change from baseline in the SGRQ total score at week 32
Notes 32-week treatment intervention, with 1 to 6 weeks run-in and 8-week followup. Con-
ducted in Baltimore, Middlesex, Ghent, Vancouver, Parma, Marseille and Paris
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Centralised computer-generated permuted
block schedule
Allocation concealment (selection bias) Low risk Treatment allocations will be concealed via
the RandAll system
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Mepolizumab and placebo were identical
in appearance and were administered by a
staffmember whowas unaware of the study
group assignments
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The study drugs were prepared by staff
members who were aware of the study
group assignments but were not involved
in study assessments
Incomplete outcome data (attrition bias)
All outcomes
Low risk 6% (placebo), 8% (IV), 5% ( SC) did not
complete the study
Selective reporting (reporting bias) Low risk All outcome measures reported
Pavord 2012
Methods Multicentre, double-blind, placebo-controlled trial
Participants People with severe asthma despite receiving high doses of standard asthma medications
Inclusion criteria:
• Male or female
• Aged 12 to 65 years inclusive
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Pavord 2012 (Continued)
• Minimum weight 45 kg
• Clinical features of severe refractory asthma
• Well-documented requirement for high dose ICS(i.e. ≥ 880 mcg/day fluticasone
propionate or equivalent daily) for at least 12 months
• Use of additional controller medication in addition to high dose ICS for at least
12 months
• Persistent airflow obstruction indicated by a pre-bronchodilator FEV1 < 80%
predicted at visit 1 or 2 or peak flow diurnal variability of > 20% on 3 or more days
during the run-in
• Airway inflammation likely to be eosinophilic in nature, demonstrated by either
raised peripheral blood eosinophils (≥ 300/µL), sputum eosinophils (≥ 3%), exhaled
nitric oxide (≥50 ppb) or prompt deterioration of asthma control following a ≤ 25%
reduction in regular maintenance dose of ICS or OCS
• History of ≥ 2 exacerbations requiring systemic corticosteroids in the previous 12
months
• Evidence of asthma documented by airway reversibility, airway
hyperresponsiveness or airflow variability
• ECG assessment demonstrating QTc < 450 ms or QTc < 480 ms for patients
with bundle branch block
• Liver function tests on surrogate markers for liver disease, demonstrating ALT< 2
x ULN, AST < 2 x ULN, Alk Phos ≤ 1.5 x ULN, bilirubin ≤ 1.5 x ULN
• Female of non-child-bearing potential or child-bearing potential with a negative
pregnancy test at screening and prepared to use an acceptable method of contraception
• Able to give written informed consent
• Able to read, comprehend and write at a sufficient level to complete study
materials
Exclusion Criteria:
• Current smokers or smoking history of ≥ 10 pack years
• Clinically important lung condition other than asthma
• Diagnosis or suspicion of malignancy
• Unstable liver disease
• Churg-Strauss syndrome
• Use of methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine or any
experimental anti-inflammatory therapy within 3 months of screening
• Administration of omalizumab (Xolair) or any other biological agent for the
treatment of inflammatory disease within 6 months of visit 1
• Regular use of OCS or systemic corticosteroids for diseases other than asthma
within 12 months; any intra-articular, short-acting intramuscular corticosteroid within
1 month; or intramuscular, long-acting depot corticosteroid within 3 months
• Allergy/intolerance to the excipients in the mepolizumab formulation
• Administration of any investigational drug in previous 30 days or 5 terminal half-
lives, whichever is longer
• Pregnant, breastfeeding or planning to become pregnant
• Clinically significant disease which is uncontrolled with standard treatment
• History of alcohol misuse or substance abuse
• Parasitic infestation within previous 6 months
• Known immunodeficiency
• Unable to follow instructions, use the electronic diary or peak flow meter
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Pavord 2012 (Continued)
• Known evidence of lack of adherence to controller medications, inability to
follow physician’s recommendations, or both
• Previous participation in a study of mepolizumab and received study medication
within 90 days
• 621 patients were randomised: 156 were assigned to 750 mg mepolizumab, 152
to 250 mg mepolizumab, 154 to 75 mg mepolizumab, and 159 to placebo
Interventions 13 total intravenous infusions of mepolizumab (750 mg), mepolizumab (250 mg),
mepolizumab (75 mg) or placebo given every 4 weeks
Outcomes Primary outcome:
• Frequency of clinically significant exacerbations of asthma
Secondary outcomes:
• Time to first clinically significant exacerbation requiring oral or systemic
corticosteroids, hospitalisation, and/or ED visits
• Frequency of exacerbations requiring hospitalisation (including intubation and
admittance to an ICU) or ED visits
• Time to first exacerbation requiring hospitalisation or ED visit
• Frequency of investigator-defined exacerbations
• Time to first investigator-defined exacerbation
• Mean change from baseline in clinic pre-bronchodilator FEV1 over the 52-week
treatment period
• Mean change from baseline in clinic post-bronchodilator FEV1 over the 52-week
treatment period
• Mean change from baseline in ACQ score
Notes 52-week study conducted at 81 centres in 13 countries (Argentina, Australia, Canada,
Chile, France, Germany, South Korea, Poland, Romania, Russia, Ukraine, the UK and
the USA)
Supported by GlaxoSmithKline
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Central telephone-based system and com-
puter-generated randomly permuted block
schedule stratified by whether treatment
with oral corticosteroids was required
Allocation concealment (selection bias) Low risk Mepolizumab and placebo were prepared
by unmasked site staff who were not in-
volved in study assessments
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Mepolizumab and placebo were prepared
by unmasked site staff who were not in-
volved in study assessments. Both treat-
ments were identical in appearance and
were given to patients by amaskedmember
42Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pavord 2012 (Continued)
of the site staff
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Data analysts were masked to treatment al-
location
Incomplete outcome data (attrition bias)
All outcomes
Low risk All patients accounted forwith information
on reasons for having withdrawn. Some pa-
tients not included in results due to ‘poor
efficacy’
Selective reporting (reporting bias) Low risk No apparent indication of reporting bias
ACQ: Asthma Control Questionnaire; ALT: alanine aminotransferase; Alk Phos: alkaline phosphatase; AQLQ: Asthma Quality of
Life Questionnaire; AST: aspartate aminotransferase; ECP: eosinophil cationic protein; ED: emergency department; FEV1 : Forced
expiratory volume in 1 second; FVC: forced vital capacity; HRQoL: health-related quality of life; ICS: inhaled corticosteroid; IL:
interleukin; IV: intravenous; JACQ: Juniper AsthmaControl Questionnaire;OCS: oral corticosteroids; PC20 : histamine provocative
concentration causing a 20% drop in FEV1;PEFR: peak expiratory flow rate; SC: subcutaneous; SD: standard deviation; SGRQ:
St. George’s Respiratory Questionnaire; ULN: Upper Limit of Normal; VC: vital capacity.
aQTc(F): a measure of the time between the start of the Q wave and the end of the T wave in the heart’s electrical cycle, corrected for
the heart rate using Fredericia’s formula.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alvarez-Cuesta 1994 Study does not include mepolizumab
Armentia 1992 Study does not include mepolizumab
Ayres 2004 Study does not include mepolizumab
Bel 2014 Focus of trial is on steroid reduction and therefore does not meet our predefined inclusion criteria
Berger 2003 Study does not include mepolizumab
Blanken 2012 Study does not include mepolizumab
Blanken 2013 Study does not include mepolizumab
Boulet 1997 Study does not include mepolizumab
Bousquet 2004 Study does not include mepolizumab
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Bousquet 2011 Study does not include mepolizumab
Brown 2007 Study does not include mepolizumab
Bryant 1975 Study does not include mepolizumab
Bryant 1975a Study does not include mepolizumab
Buhl 2000a Study does not include mepolizumab
Buhl 2000b Study does not include mepolizumab
Buhl 2002 Study does not include mepolizumab
Bush 1985 Study does not include mepolizumab
Busse 2001 Study does not include mepolizumab
Busse 2008 Study does not include mepolizumab
Caffarelli 2000 Study does not include mepolizumab
Castro 2010 Does not include Mepolizumab
Castro 2011 Does not include Mepolizumab
Chandra 1989 Study does not include mepolizumab
Chervinsky 2003 Study does not include mepolizumab
Clavel 1998 Study does not include mepolizumab
Corren 2003 Study does not include mepolizumab
Corren 2010 Study does not include mepolizumab
Cullell-Young 2002 Study does not include mepolizumab
De Boever 2014 Study does not include mepolizumab
Djukanovic 2004 Study does not include mepolizumab
Ebner 1989 Study does not include mepolizumab
Eckman 2010 Study does not include mepolizumab
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El-Nawawy 2000 Study does not include mepolizumab
Fahy 1997 Study does not include mepolizumab
Fahy 1999 Study does not include mepolizumab
Finn 2003 Study does not include mepolizumab
Frew 1998 Study does not include mepolizumab
Garcia 2013 Study does not include mepolizumab
Gauvreau 2011 Study does not include mepolizumab
Gauvreau 2014a Study does not include mepolizumab
Gauvreau 2014b Study does not include mepolizumab
Gauvreau 2014c Study does not include mepolizumab
Gevaert 2013 Study does not include mepolizumab
Gordon 1972 Study does not include mepolizumab
Greenberg 1991 Study does not include mepolizumab
Han 2009 Study does not include mepolizumab
Hanania 2011 Study does not include mepolizumab
Hanania 2013 Study does not include mepolizumab
Hanania 2014 Study does not include mepolizumab
Hill 1982 Study does not include mepolizumab
Hodsman 2013 Study does not include mepolizumab
Holgate 2004 Study does not include mepolizumab
Hoshino 2012 Study does not include mepolizumab
Humbert 2005 Study does not include mepolizumab
Humbert 2008 Study does not include mepolizumab
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Humbert 2009 Study does not include mepolizumab
Jacquemin 1995 Study does not include mepolizumab
Jutel 2005 Study does not include mepolizumab
Kang 1988 Study does not include mepolizumab
Kips 2003 Study does not include mepolizumab
Kon 2001 Study does not include mepolizumab
Kopp 2009 Study does not include mepolizumab
Kopp 2013 Study does not include mepolizumab
Kulus 2010 Study does not include mepolizumab
Lanier 2003 Study does not include mepolizumab
Lanier 2009 Study does not include mepolizumab
Laviolette 2013 Study does not include mepolizumab
Leynadier 2004 Study does not include mepolizumab
Lizaso 2008 Study does not include mepolizumab
Massanari 2009 Study does not include mepolizumab
Massanari 2010 Study does not include mepolizumab
Mathur 2011 Study does not include Mepolizumab
Metzger 1998 Study does not include mepolizumab
Milgrom 1999 Study does not include mepolizumab
Milgrom 2001 Study does not include mepolizumab
Modlin 1977 Study does not include mepolizumab
Moss 1987 Study does not include mepolizumab
Nair 2010 Study does not include mepolizumab
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NCT00802438 Non randomised study
NCT01366521 Phase 2 study comparing three doses of Mepolizumab. This trial does not have a placebo arm
NCT01471327 Focus of study was on tolerability, pharmacokinetics and pharmacodynamics of single dose SB-240563
administered intravenously to Japanese healthy male subjects. Patients with asthma were not included in the
study
NCT01691859 This study does not include a placebo group. Multi-centre, open-label, long term safety study with total
sample receiving 100 milligrams (mg) mepolizumab administered subcutaneously (no control group)
NCT01842607 This study does not include a placebo group. Multi-centre, open-label, long term safety study with total
sample receiving 100 milligrams (mg) mepolizumab administered subcutaneously (no control group)
NCT02135692 This study does not include a placebo group.Multi-center, open-label, long-term study of subcutaneously (SC)
administered mepolizumab 100mg in addition to standard of care (SOC), in subjects with severe eosinophilic
asthma
NCT02293265 Study does not include mepolizumab (aim of study is to provide a ’reliable description of the severe asthma
patient landscape with respect to the potential eligibility for treatment with mepolizumab, omalizumab, and
reslizumab’),
Niven 2008 Study does not include mepolizumab
Noga 2003 Study does not include mepolizumab
Noga 2008 Study does not include mepolizumab
Noonan 2013 Study does not include mepolizumab
Oba 2004 Study does not include mepolizumab
Oh 2013 Study does not include mepolizumab
Ohashi 1997 Study does not include mepolizumab
Ohman 1984 Study does not include mepolizumab
Ohta 2009 Study does not include mepolizumab
Ong 2005 Study does not include mepolizumab
Parker 2010 Study does not include mepolizumab
Pauli 1984 Study does not include mepolizumab
Piper 2013 Study does not include mepolizumab
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Prieto 2006 Study does not include mepolizumab
Pui 2010 Study does not include mepolizumab
Rose 2009 Study does not include mepolizumab
Sakamoto 1984 Study does not include mepolizumab
Scheerens 2011 Study does not include mepolizumab
Scheerens 2014 Study does not include mepolizumab
Siergiejko 2011 Study does not include mepolizumab
Silk 1998 Study does not include mepolizumab
Silkoff 2004 Study does not include mepolizumab
Simoes 2007 Study does not include mepolizumab
Singh 2010 Study does not include mepolizumab
Slavin 2009 Study does not include mepolizumab
Soler 2001 Study does not include mepolizumab
Sorkness 2013 Does not include Mepolizumab
Sthoeger 2007 Study does not include mepolizumab
Sugaya 1994 Study does not include mepolizumab
Swanson 2014 Study does not include mepolizumab
Szymaniak 1998 Study does not include mepolizumab
Tanaka 1993 Study does not include mepolizumab
Terr 1969 Study does not include mepolizumab
Van Rensen 2009 Study does not include mepolizumab
Vignola 2004 Study does not include mepolizumab
Wark 2003 Study does not include mepolizumab
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Wenzel 2009 Study does not include mepolizumab
Wenzel 2013 Study does not include mepolizumab
Zetterstrom 1972 Study does not include mepolizumab
Zhu 2013 Study does not include mepolizumab
Zielen 2013 Study does not include mepolizumab
Characteristics of ongoing studies [ordered by study ID]
NCT01520051 2012
Trial name or title Mepolizumab treatment for rhinovirus-induced asthma exacerbations (MATERIAL)
Methods Randomised double blind trial
Participants Mild allergic asthma patients with viral airway infections
Inclusion criteria:
• Age: from 18 to 50 years
• History of episodic chest tightness and wheezing
• Intermittent or mild persistent asthma according to the criteria of the Global Initiative for Asthma
• Non-smoking or stopped smoking more than 12 months ago and ≤ 5 pack-years
• Clinically stable, no history of exacerbations within 6 weeks prior to the study
• Steroid-naïve or those not currently on corticosteroids and who have not taken any corticosteroids by
any dosing routes within 2 weeks prior to the study. Occasional usage of inhaled short-acting beta2-agonists
as rescue medication is allowed, prior to and during the study
• Baseline FEV1 > 80% of predicted
• Airway hyperresponsiveness, indicated by a positive acetyl-beta-methylcholine bromide (MeBr)
challenge with PC20 < 9.8 mg/mL
• Positive skin prick test (SPT) to one or more of the 12 common aeroallergen extracts, defined as a
wheal with an average diameter over 3 mm
• No other clinically significant abnormality on medical history and clinical examination
Exclusion Criteria:
• Presence of antibodies directed against RV16 in serum (titre > 4), measured at visit 1
• History of clinical significant hypotensive episodes or symptoms of fainting, dizziness, or light-
headedness
• Women who are pregnant, lactating or who have a positive urine pregnancy test at visit 1
• Chronic use of any other medication for treatment of lung disease other than short-acting beta2-
agonists
• Participation in any clinical investigational drug treatment protocol in previous 3 months
• Ongoing use of tobacco products of any kind or previous usage with ≥ 6 total pack-years
• Concomitant disease or condition which could interfere with the conduct of the study, or for which
the treatment might interfere with the conduct of the study, or which would, in the opinion of the
investigator, pose an unacceptable risk to the patient
• People with young children (< 2 years)
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NCT01520051 2012 (Continued)
Interventions 3 monthly intravenous infusions of 750 mg versus 3 monthly intravenous infusions with saline
Outcomes Primary outcome measures:
• FEV1 1 day prior and 6 days after RV16 challenge
• Questionnaire to score asthma and common cold complaints during 14 days following viral infection
Secondary outcome measures:
• Viral load on day 6 after viral infection
• Sputum eosinophils before and after mepolizumab infusion
• Cell influx in bronchoalveolar lavage fluid 6 days after viral infection
• Pro-inflammatory cytokines in bronchoalveolar lavage fluid 6 days after viral infection
• Antibody production 6 weeks after infection
Starting date January 2012
Contact information Suzanne Bal, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Notes
NCT02281318 2014
Trial name or title A randomised, double-blind, placebo-controlled, parallel-group, multi-centre, 24-week study to evaluate the
efficacy and safety of mepolizumab adjunctive therapy in subjects with severe eosinophilic asthma on markers
of asthma control
Methods Multicentre, placebo-controlled, double-blind, parallel-group study
Participants People with severe eosinophilic asthma. Approximately 780 participants with severe eosinophilic asthma will
be screened to ensure the randomisation of 544 participants (272 participants per treatment group) into the
study
Interventions Mepolizumab 100 mg subcutaneously into the upper arm or thigh every 4 weeks for a period of 24 weeks
(total of 6 doses) along with their respective standard care of treatment,
versus
placebo (0.9% sodium chloride) subcutaneously into the upper arm or thigh every 4 weeks for a period of 24
weeks (total of 6 doses) along with their respective standard care of treatment
Outcomes Primary Outcome Measure:
• Mean change from baseline in St. George’s Respiratory Questionnaire (SGRQ) score at week 24
Secondary Outcome Measures:
• Mean change from baseline in clinic pre-bronchodilator FEV1 at week 24
• Percentage of participants achieving a 4 point or greater reduction from baseline in SGRQ score at
week 24
• Mean change from baseline in five-item Asthma Control Questionnaire (ACQ-5) score at week 24
Starting date December 2014
Contact information US GSK Clinical Trials Call Center: GSKClinicalSupportHD@gsk.com
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NCT02281318 2014 (Continued)
Notes Estimated primary completion date: 2016
FEV1 : Forced expiratory volume in 1 second; PC20 : histamine provocative concentration causing a 20% drop in FEV1
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D A T A A N D A N A L Y S E S
Comparison 1. IV Mepolizumab versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Health-related quality of life
(AQLQ)
2 Mean Difference (Random, 95% CI) Subtotals only
1.1 AQLQ 2 677 Mean Difference (Random, 95% CI) 0.21 [-0.01, 0.44]
2 Health-related quality of life
(SGRQ)
1 Mean Difference (Random, 95% CI) Subtotals only
2.1 SGRQ 1 Mean Difference (Random, 95% CI) -6.4 [-9.65, -3.15]
3 Rate of clinically significant
exacerbations
2 Rate Ratio (Random, 95% CI) Subtotals only
3.1 75 mg mepolizumab
versus placebo
2 690 Rate Ratio (Random, 95% CI) 0.52 [0.43, 0.64]
3.2 250 mg mepolizumab
versus placebo
1 307 Rate Ratio (Random, 95% CI) 0.61 [0.46, 0.81]
3.3 750 mg mepolizumab
versus placebo
1 311 Rate Ratio (Random, 95% CI) 0.48 [0.36, 0.64]
4 Rate of exacerbations requiring
admission
2 Rate Ratio (Random, 95% CI) Subtotals only
4.1 75 mg mepolizumab
versus placebo
2 690 Rate Ratio (Random, 95% CI) 0.61 [0.33, 1.13]
4.2 250 mg mepolizumab
versus placebo
1 307 Rate Ratio (Random, 95% CI) 0.65 [0.31, 1.37]
4.3 750 mg mepolizumab
versus placebo
1 311 Rate Ratio (Random, 95% CI) 0.37 [0.16, 0.86]
5 Rate of exacerbations requiring
ED or admission
2 Rate Ratio (Random, 95% CI) Subtotals only
5.1 75 mg mepolizumab
versus placebo
2 690 Rate Ratio (Random, 95% CI) 0.52 [0.31, 0.87]
5.2 250 mg mepolizumab
versus placebo
1 307 Rate Ratio (Random, 95% CI) 0.58 [0.30, 1.12]
5.3 750 mg mepolizumab
versus placebo
1 311 Rate Ratio (Random, 95% CI) 0.52 [0.27, 1.02]
6 People with one or more
exacerbations
4 467 Risk Ratio (M-H, Random, 95% CI) 0.67 [0.34, 1.31]
7 Serious adverse events 5 1441 Risk Ratio (M-H, Random, 95% CI) 0.49 [0.30, 0.80]
8 FEV1 (litres) 1 Mean Difference (Random, 95% CI) Subtotals only
8.1 250 mg mepolizumab
versus placebo
1 246 Mean Difference (Random, 95% CI) -0.03 [-0.13, 0.07]
8.2 750 mg mepolizumab
versus placebo
1 242 Mean Difference (Random, 95% CI) 0.02 [-0.10, 0.14]
9 PEFR (L/min) 1 Mean Difference (Random, 95% CI) Subtotals only
9.1 250 mg mepolizumab
versus placebo
1 246 Mean Difference (Random, 95% CI) 13.49 [0.71, 26.27]
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9.2 750 mg mepolizumab
versus placebo
1 242 Mean Difference (Random, 95% CI) 3.42 [-9.40, 16.24]
10 Post bronchodilator FEV1 (L) 3 Mean Difference (Random, 95% CI) Totals not selected
10.1 6 weeks 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
10.2 32 weeks 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
10.3 1 year 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
11 Percentage predicted FEV1
after bronchodilation
1 Mean Difference (Random, 95% CI) Totals not selected
11.1 6 weeks 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
12 Pre-bronchodilator FEV1 (L)
at week 32
1 Mean Difference (Random, 95% CI) Totals not selected
12.1 75 mg mepolizumab
versus placebo
1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
13 Pre-bronchodilator FEV1 (mL)
at week 52
1 Mean Difference (Random, 95% CI) Subtotals only
13.1 75 mg mepolizumab
versus placebo
1 308 Mean Difference (Random, 95% CI) 61.00 [-37.00, 161.
00]
13.2 250 mg mepolizumab
versus placebo
1 307 Mean Difference (Random, 95% CI) 81.00 [-18.51, 180.
51]
13.3 750 mg mepolizumab
versus placebo
1 311 Mean Difference (Random, 95% CI) 56.0 [-41.00, 155.
00]
14 Late asthmatic reaction
(maximum % fall in FEV1)
1 Mean Difference (Random, 95% CI) Subtotals only
14.1 2.5 mg/kg mepolizumab
versus placebo
1 16 Mean Difference (Random, 95% CI) 3.50 [-3.46, 10.46]
14.2 7.5 mg/kg mepolizumab
versus placebo
1 16 Mean Difference (Random, 95% CI) 0.3 [-6.50, 7.10]
15 Asthma symptoms 5 Mean Difference (Random, 95% CI) Subtotals only
15.1 75 mg mepolizumab
versus placebo
2 690 Mean Difference (Random, 95% CI) -0.30 [-0.55, -0.04]
15.2 250 mg mepolizumab
versus placebo
2 553 Mean Difference (Random, 95% CI) -0.24 [-0.48, 0.01]
15.3 750 mg mepolizumab
versus placebo
4 631 Mean Difference (Random, 95% CI) -0.02 [-0.57, 0.54]
16 Asthma symptoms (JACQ) 2 80 Mean Difference (IV, Random, 95% CI) -0.04 [-0.42, 0.35]
Comparison 2. SC Mepolizumab versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Health-related quality of life 1 Mean Difference (Random, 95% CI) Totals not selected
1.1 SGRQ 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
2 Rate of exacerbations requiring
admission
1 Rate Ratio (Random, 95% CI) Totals not selected
3 Rate of exacerbations requiring
ED or admission
1 Rate Ratio (Random, 95% CI) Totals not selected
4 Rate of clinically significant
exacerbations
1 Rate Ratio (Random, 95% CI) Totals not selected
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5 Pre bronchodilator FEV1 (litres) 1 Mean Difference (Random, 95% CI) Totals not selected
5.1 32 weeks 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
6 Post bronchodilator FEV1
(litres)
1 Mean Difference (Random, 95% CI) Totals not selected
6.1 32 weeks 1 Mean Difference (Random, 95% CI) 0.0 [0.0, 0.0]
7 Asthma symptoms 1 Mean Difference (Random, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 IV Mepolizumab versus placebo, Outcome 1 Health-related quality of life
(AQLQ).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 1 Health-related quality of life (AQLQ)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 AQLQ
Haldar 2009 29 32 0.35 (0.14) 40.9 % 0.35 [ 0.08, 0.62 ]
Pavord 2012 461 155 0.12 (0.1) 59.1 % 0.12 [ -0.08, 0.32 ]
Subtotal (95% CI) 490 187 100.0 % 0.21 [ -0.01, 0.44 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.79, df = 1 (P = 0.18); I2 =44%
Test for overall effect: Z = 1.89 (P = 0.058)
-1 -0.5 0 0.5 1
Favours placebo Favours mepolizumab
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Analysis 1.2. Comparison 1 IV Mepolizumab versus placebo, Outcome 2 Health-related quality of life
(SGRQ).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 2 Health-related quality of life (SGRQ)
Study or subgroup Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
IV,Random,95% CI IV,Random,95% CI
1 SGRQ
Ortega 2014 -6.4 (1.66) 100.0 % -6.40 [ -9.65, -3.15 ]
Subtotal (95% CI) 100.0 % -6.40 [ -9.65, -3.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00012)
-4 -2 0 2 4
Favours mepolizumab Favours placebo
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Analysis 1.3. Comparison 1 IV Mepolizumab versus placebo, Outcome 3 Rate of clinically significant
exacerbations.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 3 Rate of clinically significant exacerbations
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Pavord 2012 153 155 -0.6539 (0.1443) 51.7 % 0.52 [ 0.39, 0.69 ]
Ortega 2014 191 191 -0.6349 (0.1492) 48.3 % 0.53 [ 0.40, 0.71 ]
Subtotal (95% CI) 344 346 100.0 % 0.52 [ 0.43, 0.64 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 6.22 (P < 0.00001)
2 250 mg mepolizumab versus placebo
Pavord 2012 152 155 -0.4943 (0.1447) 100.0 % 0.61 [ 0.46, 0.81 ]
Subtotal (95% CI) 152 155 100.0 % 0.61 [ 0.46, 0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.42 (P = 0.00064)
3 750 mg mepolizumab versus placebo
Pavord 2012 156 155 -0.734 (0.1468) 100.0 % 0.48 [ 0.36, 0.64 ]
Subtotal (95% CI) 156 155 100.0 % 0.48 [ 0.36, 0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.00 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.40, df = 2 (P = 0.50), I2 =0.0%
0.5 0.7 1 1.5 2
Favours mepolizumab Favours placebo
56Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.4. Comparison 1 IV Mepolizumab versus placebo, Outcome 4 Rate of exacerbations requiring
admission.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 4 Rate of exacerbations requiring admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Ortega 2014 191 191 -0.4943 (0.5108) 38.0 % 0.61 [ 0.22, 1.66 ]
Pavord 2012 153 155 -0.49 (0.4) 62.0 % 0.61 [ 0.28, 1.34 ]
Subtotal (95% CI) 344 346 100.0 % 0.61 [ 0.33, 1.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
2 250 mg mepolizumab versus placebo
Pavord 2012 152 155 -0.43 (0.38) 100.0 % 0.65 [ 0.31, 1.37 ]
Subtotal (95% CI) 152 155 100.0 % 0.65 [ 0.31, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
3 750 mg mepolizumab versus placebo
Pavord 2012 156 155 -0.99 (0.43) 100.0 % 0.37 [ 0.16, 0.86 ]
Subtotal (95% CI) 156 155 100.0 % 0.37 [ 0.16, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.30 (P = 0.021)
Test for subgroup differences: Chi2 = 1.14, df = 2 (P = 0.57), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.5. Comparison 1 IV Mepolizumab versus placebo, Outcome 5 Rate of exacerbations requiring
ED or admission.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 5 Rate of exacerbations requiring ED or admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Weight Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Ortega 2014 191 191 -0.3857 (0.3721) 48.4 % 0.68 [ 0.33, 1.41 ]
Pavord 2012 153 155 -0.9163 (0.36) 51.6 % 0.40 [ 0.20, 0.81 ]
Subtotal (95% CI) 344 346 100.0 % 0.52 [ 0.31, 0.87 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 2.49 (P = 0.013)
2 250 mg mepolizumab versus placebo
Pavord 2012 152 155 -0.5447 (0.3357) 100.0 % 0.58 [ 0.30, 1.12 ]
Subtotal (95% CI) 152 155 100.0 % 0.58 [ 0.30, 1.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.62 (P = 0.10)
3 750 mg mepolizumab versus placebo
Pavord 2012 156 155 -0.6539 (0.3437) 100.0 % 0.52 [ 0.27, 1.02 ]
Subtotal (95% CI) 156 155 100.0 % 0.52 [ 0.27, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 0.08, df = 2 (P = 0.96), I2 =0.0%
0.2 0.5 1 2 5
Favours mepolizumab Favours placebo
58Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.6. Comparison 1 IV Mepolizumab versus placebo, Outcome 6 People with one or more
exacerbations.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 6 People with one or more exacerbations
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Flood-Page 2003 0/11 0/13 Not estimable
Flood-Page 2007 17/236 11/126 35.3 % 0.83 [ 0.40, 1.71 ]
Haldar 2009 20/29 27/32 54.0 % 0.82 [ 0.61, 1.09 ]
Nair 2009 1/9 10/11 10.8 % 0.12 [ 0.02, 0.78 ]
Total (95% CI) 285 182 100.0 % 0.67 [ 0.34, 1.31 ]
Total events: 38 (Mepolizumab), 48 (Placebo)
Heterogeneity: Tau2 = 0.20; Chi2 = 4.87, df = 2 (P = 0.09); I2 =59%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
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Analysis 1.7. Comparison 1 IV Mepolizumab versus placebo, Outcome 7 Serious adverse events.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 7 Serious adverse events
Study or subgroup Mepolizumab Placebo Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Flood-Page 2007 5/236 4/126 14.9 % 0.67 [ 0.18, 2.44 ]
Haldar 2009 3/29 11/32 18.3 % 0.30 [ 0.09, 0.97 ]
Nair 2009 0/9 0/11 Not estimable
Ortega 2014 14/191 27/191 66.8 % 0.52 [ 0.28, 0.96 ]
Pavord 2012 0/461 0/155 Not estimable
Total (95% CI) 926 515 100.0 % 0.49 [ 0.30, 0.80 ]
Total events: 22 (Mepolizumab), 42 (Placebo)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.91, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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Analysis 1.8. Comparison 1 IV Mepolizumab versus placebo, Outcome 8 FEV1 (litres).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 8 FEV1 (litres)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 250 mg mepolizumab versus placebo
Flood-Page 2007 120 126 -0.03 (0.05) 100.0 % -0.03 [ -0.13, 0.07 ]
Subtotal (95% CI) 120 126 100.0 % -0.03 [ -0.13, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
2 750 mg mepolizumab versus placebo
Flood-Page 2007 116 126 0.02 (0.06) 100.0 % 0.02 [ -0.10, 0.14 ]
Subtotal (95% CI) 116 126 100.0 % 0.02 [ -0.10, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
Test for subgroup differences: Chi2 = 0.41, df = 1 (P = 0.52), I2 =0.0%
-0.2 -0.1 0 0.1 0.2
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Analysis 1.9. Comparison 1 IV Mepolizumab versus placebo, Outcome 9 PEFR (L/min).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 9 PEFR (L/min)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 250 mg mepolizumab versus placebo
Flood-Page 2007 120 126 13.49 (6.52) 100.0 % 13.49 [ 0.71, 26.27 ]
Subtotal (95% CI) 120 126 100.0 % 13.49 [ 0.71, 26.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.039)
2 750 mg mepolizumab versus placebo
Flood-Page 2007 116 126 3.42 (6.54) 100.0 % 3.42 [ -9.40, 16.24 ]
Subtotal (95% CI) 116 126 100.0 % 3.42 [ -9.40, 16.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi2 = 1.19, df = 1 (P = 0.28), I2 =16%
-20 -10 0 10 20
Favours placebo Favours mepolizumab
62Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.10. Comparison 1 IV Mepolizumab versus placebo, Outcome 10 Post bronchodilator FEV1 (L).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 10 Post bronchodilator FEV1 (L)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 6 weeks
Nair 2009 7 10 -0.2 (0.44) -0.20 [ -1.06, 0.66 ]
2 32 weeks
Ortega 2014 191 191 0.146 (0.049) 0.15 [ 0.05, 0.24 ]
3 1 year
Haldar 2009 29 32 -0.05 (0.1) -0.05 [ -0.25, 0.15 ]
-1 -0.5 0 0.5 1
Favours placebo Favours mepolizumab
Analysis 1.11. Comparison 1 IV Mepolizumab versus placebo, Outcome 11 Percentage predicted FEV1 after
bronchodilation.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 11 Percentage predicted FEV1 after bronchodilation
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 6 weeks
Nair 2009 7 10 -5.9 (7.98) -5.90 [ -21.54, 9.74 ]
-20 -10 0 10 20
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Analysis 1.12. Comparison 1 IV Mepolizumab versus placebo, Outcome 12 Pre-bronchodilator FEV1 (L) at
week 32.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 12 Pre-bronchodilator FEV1 (L) at week 32
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Ortega 2014 191 191 0.1 (0.044) 0.10 [ 0.01, 0.19 ]
-0.2 -0.1 0 0.1 0.2
Favours placebo Favours mepolizumab
Analysis 1.13. Comparison 1 IV Mepolizumab versus placebo, Outcome 13 Pre-bronchodilator FEV1 (mL)
at week 52.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 13 Pre-bronchodilator FEV1 (mL) at week 52
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Pavord 2012 153 155 61 (51.02) 100.0 % 61.00 [ -39.00, 161.00 ]
Subtotal (95% CI) 153 155 100.0 % 61.00 [ -39.00, 161.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
2 250 mg mepolizumab versus placebo
Pavord 2012 152 155 81 (50.77) 100.0 % 81.00 [ -18.51, 180.51 ]
Subtotal (95% CI) 152 155 100.0 % 81.00 [ -18.51, 180.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
-500 -250 0 250 500
Favours placebo Favours mepolizumab
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(. . . Continued)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
3 750 mg mepolizumab versus placebo
Pavord 2012 156 155 56 (50.51) 100.0 % 56.00 [ -43.00, 155.00 ]
Subtotal (95% CI) 156 155 100.0 % 56.00 [ -43.00, 155.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.11 (P = 0.27)
Test for subgroup differences: Chi2 = 0.14, df = 2 (P = 0.93), I2 =0.0%
-500 -250 0 250 500
Favours placebo Favours mepolizumab
Analysis 1.14. Comparison 1 IV Mepolizumab versus placebo, Outcome 14 Late asthmatic reaction
(maximum % fall in FEV1).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 14 Late asthmatic reaction (maximum % fall in FEV1)
Study or subgroup Experimental Control Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 2.5 mg/kg mepolizumab versus placebo
Leckie 2000 8 8 3.5 (3.55) 100.0 % 3.50 [ -3.46, 10.46 ]
Subtotal (95% CI) 8 8 100.0 % 3.50 [ -3.46, 10.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 7.5 mg/kg mepolizumab versus placebo
Leckie 2000 8 8 0.3 (3.47) 100.0 % 0.30 [ -6.50, 7.10 ]
Subtotal (95% CI) 8 8 100.0 % 0.30 [ -6.50, 7.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Test for subgroup differences: Chi2 = 0.42, df = 1 (P = 0.52), I2 =0.0%
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Analysis 1.15. Comparison 1 IV Mepolizumab versus placebo, Outcome 15 Asthma symptoms.
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 15 Asthma symptoms
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference Weight
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 75 mg mepolizumab versus placebo
Ortega 2014 191 191 -0.42 (0.1) 53.3 % -0.42 [ -0.62, -0.22 ]
Pavord 2012 153 155 -0.16 (0.12) 46.7 % -0.16 [ -0.40, 0.08 ]
Subtotal (95% CI) 344 346 100.0 % -0.30 [ -0.55, -0.04 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 2.30 (P = 0.021)
2 250 mg mepolizumab versus placebo
Flood-Page 2007 120 126 -0.12 (0.27) 21.2 % -0.12 [ -0.65, 0.41 ]
Pavord 2012 152 155 -0.27 (0.14) 78.8 % -0.27 [ -0.54, 0.00 ]
Subtotal (95% CI) 272 281 100.0 % -0.24 [ -0.48, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.92 (P = 0.055)
3 750 mg mepolizumab versus placebo
Flood-Page 2007 116 126 0.39 (0.27) 40.3 % 0.39 [ -0.14, 0.92 ]
Haldar 2009 29 32 -4.5 (4.83) 0.3 % -4.50 [ -13.97, 4.97 ]
Nair 2009 7 10 -2.1 (1.87) 2.2 % -2.10 [ -5.77, 1.57 ]
Pavord 2012 156 155 -0.2 (0.12) 57.1 % -0.20 [ -0.44, 0.04 ]
Subtotal (95% CI) 308 323 100.0 % -0.02 [ -0.57, 0.54 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 5.95, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Chi2 = 0.81, df = 2 (P = 0.67), I2 =0.0%
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Analysis 1.16. Comparison 1 IV Mepolizumab versus placebo, Outcome 16 Asthma symptoms (JACQ).
Review: Mepolizumab versus placebo for asthma
Comparison: 1 IV Mepolizumab versus placebo
Outcome: 16 Asthma symptoms (JACQ)
Study or subgroup Mepolizumab Placebo
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Haldar 2009 29 -0.17 (0.82) 32 -0.21 (0.91) 77.7 % 0.04 [ -0.39, 0.47 ]
Nair 2009 9 1.3 (0.9) 10 1.6 (0.9) 22.3 % -0.30 [ -1.11, 0.51 ]
Total (95% CI) 38 42 100.0 % -0.04 [ -0.42, 0.35 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
Test for subgroup differences: Not applicable
-1 -0.5 0 0.5 1
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Analysis 2.1. Comparison 2 SC Mepolizumab versus placebo, Outcome 1 Health-related quality of life.
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 1 Health-related quality of life
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 SGRQ
Ortega 2014 194 191 -7 (1.63) -7.00 [ -10.19, -3.81 ]
-10 -5 0 5 10
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Analysis 2.2. Comparison 2 SC Mepolizumab versus placebo, Outcome 2 Rate of exacerbations requiring
admission.
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 2 Rate of exacerbations requiring admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ortega 2014 194 191 -1.1712 (0.5494) 0.31 [ 0.11, 0.91 ]
0.01 0.1 1 10 100
Favours mepolizumab Favours placebo
Analysis 2.3. Comparison 2 SC Mepolizumab versus placebo, Outcome 3 Rate of exacerbations requiring
ED or admission.
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 3 Rate of exacerbations requiring ED or admission
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ortega 2014 194 191 -0.9416 (0.3854) 0.39 [ 0.18, 0.83 ]
0.01 0.1 1 10 100
Favours mepolizumab Favours placebo
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Analysis 2.4. Comparison 2 SC Mepolizumab versus placebo, Outcome 4 Rate of clinically significant
exacerbations.
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 4 Rate of clinically significant exacerbations
Study or subgroup Mepolizumab Placebo log [Rate Ratio] Rate Ratio Rate Ratio
N N (SE) IV,Random,95% CI IV,Random,95% CI
Ortega 2014 194 191 -0.755 (0.1495) 0.47 [ 0.35, 0.63 ]
0.2 0.5 1 2 5
Favours mepolizumab Favours placebo
Analysis 2.5. Comparison 2 SC Mepolizumab versus placebo, Outcome 5 Pre bronchodilator FEV1 (litres).
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 5 Pre bronchodilator FEV1 (litres)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 32 weeks
Ortega 2014 194 191 0.098 (0.04) 0.10 [ 0.02, 0.18 ]
-0.2 -0.1 0 0.1 0.2
Favours Placebo Favours Mepolizumab
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Analysis 2.6. Comparison 2 SC Mepolizumab versus placebo, Outcome 6 Post bronchodilator FEV1 (litres).
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 6 Post bronchodilator FEV1 (litres)
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
1 32 weeks
Ortega 2014 194 191 0.138 (0.048) 0.14 [ 0.04, 0.23 ]
-1 -0.5 0 0.5 1
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Analysis 2.7. Comparison 2 SC Mepolizumab versus placebo, Outcome 7 Asthma symptoms.
Review: Mepolizumab versus placebo for asthma
Comparison: 2 SC Mepolizumab versus placebo
Outcome: 7 Asthma symptoms
Study or subgroup Mepolizumab Placebo Mean Difference (SE)
Mean
Difference
Mean
Difference
N N IV,Random,95% CI IV,Random,95% CI
Ortega 2014 194 191 -0.44 (0.1) -0.44 [ -0.64, -0.24 ]
-1 -0.5 0 0.5 1
Favours mepolizumab Favours placebo
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A D D I T I O N A L T A B L E S
Table 1. Comparisons of study characteristics
Study Design Base-
line Asthma
severity
Baseline
treatment
SC or IV Interven-
tion
(mepolizumab)
Follow-up Primary and
secondary
outcomes
No. partici-
pants
Leckie 2000 RCT dou-
ble-blind,
placebo
Mild allergic
asthma
SABA as re-
quired
IV 10 mg/
kg versus 2.5
mg/kg versus
placebo
16 weeks Blood
eosinophils,
sputum
eosinophils,
histamine
PC20 (mg/
mL), late
asthmatic re-
action (max-
imum % fall
in FEV1)
24
Buttner
2003
RCT paral-
lel group,
multicentre
double blind
Mild or
mod-
erate asthma
(FEV1 50-
80%
predicted)
1000
mcg BDP or
equivalent
and stable
IV Three 750 or
250 mg or
placebo ev-
ery 4 weeks
for 6 months
6 months Blood
eosinophil,
ECP, inter-
feron-c pro-
ducing CD4
T-cells
19
Flood-Page
2003
2-
centre dou-
ble-blind,
placebo-
controlled,
parallel-
group study
Mild atopic
(skin prick
posi-
tive) asthma
(FEV1
>70%
predicted)
SABA as re-
quired and
no corticos-
teroids
in previous 8
weeks
IV Three doses
of either 750
mg or
placebo over
20 weeks (at
weeks 0, 4
and 8)
20 weeks Airway
eosinophils,
bone marrow
eosinophils,
blood
eosinophils,
air-
way hyperre-
sponsiveness,
FEV1, PEFR
24
Flood-Page
2007
Multicentre,
randomised,
double-
blind,
placebo-
controlled
trial
Mod-
erate asthma
(FEV1 be-
tween 50%
and 80%
predicted)
maximum
dose (BDP)
or equiv-
alent, 1000
mcg/d
IV Three
doses of ei-
ther 750 mg
or 250 mg or
placebo over
20 weeks (at
weeks 0, 4
and 8)
20 weeks Change from
base-
line morning
PEFR
recorded at
weeks 12 and
20;
asthma sum-
mary symp-
tom
scores; use of
362
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Table 1. Comparisons of study characteristics (Continued)
rescue med-
ication such
as albuterol
(salbuta-
mol); quality
of life scores;
asthma exac-
er-
bation rates;
eosinophil
counts
in blood and
sputum
Nair 2009 Ran-
domised,
double-
blind,
placebo-
controlled
trial.
Eosinophilic
asthma
Pred-
nisolone
treatment
with high-
dose ICS
IV Five doses of
either
750 mg or
placebo (ad-
ministered
in 5 monthly
infusions)
26 weeks Juniper
ACQ in
patients with
asthma or
by Likert
symptom
scores +
FEV1 in
patients with
eosinophilic
bronchitis
without
asthma); the
prednisone-
sparing
effect of
mepolimuzab
or placebo as
indicated by
the absolute
and per-
centage dose
reduction
possible
without
a clinical
exacerbation
(defined as
% sputum
eosinophilia,
FEV1 % pre-
dicted
20
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Table 1. Comparisons of study characteristics (Continued)
and metha-
choline
PC20); blood
eosinophils;
frequency of
rescue salbu-
tamol use;
time to exac-
erbation
Haldar 2009 RCT dou-
ble-blind,
placebo,
parallel-
group
Eosinophilic
asthma and
exacerba-
tions
Sputum
eosinophilia
ofmore than
3% despite
high-dose
ICS treat-
ment, and at
least two ex-
ac-
erbations in
previous 12
months
IV 750 mg ver-
sus matched
placebo (150
mL of 0.
9% saline) at
monthly in-
tervals for 1
year
50 weeks Severe exac-
erbations per
person; sec-
ondary
outcomes in-
cluded
a change in
asthma
symptoms
(AQLQ)
; FEV1 after
use of a bron-
chodilator;
air-
way hyperre-
sponsiveness;
eosinophil
counts
in the blood,
sputum
61
Pavord 2012 Multi-
centre, dou-
ble-blind,
placebo-
controlled
trial
Eosinophilic
asthma and
exacerba-
tions
High dose
ICS (i.e.
≥ 880 mcg/
day
FP or equiv-
alent daily)
for at least
12 months
IV 13 infusions
in total given
every
4 weeks of
750 mg, 250
mg, 75mgor
placebo
52 weeks Exacer-
bations; time
to first
clinically sig-
nificant exac-
erbation; fre-
quency of ex-
acerba-
tions requir-
ing hospital-
isation; time
to first exac-
erbation re-
quiring hos-
pitalisation
or ED visit;
mean change
621
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Table 1. Comparisons of study characteristics (Continued)
frombaseline
in clinic pre-
bronchodila-
tor FEV1;
mean change
frombaseline
in clinic
post-bron-
chodilator
FEV1; mean
change from
baseline in
ACQ score
Ortega 2014 Ran-
domised,
double-
blind, dou-
ble-dummy,
phase 3
study
Persistent
eosinophilic
asthma
High dose
ICS in the
12 months
prior to visit
1 with or
with-
out mainte-
nance OCS
IV and SC 75 mg IV
dose versus
100 mg SC
dose versus
placebo ev-
ery 4 weeks
for 32 weeks
32 Exac-
erbations per
year;
mean change
frombaseline
in clinic pre-
bronchodila-
tor FEV1 at
week 32;
mean change
frombaseline
in the SGRQ
total score at
week 32
576
ACQ: Asthma Control Questionnaire; AQLQ: Asthma Quality of Life Questionnaire; BDP: beclomethasone dipropionate; ECP:
eosinophil cationic protein; ED: emergency department; FEV1 : Forced expiratory volume in 1 second; FP; fluticasone propionate;
ICS; inhaled corticosteroid; IV: intravenous; PC20 : histamine provocative concentration causing a 20% drop in FEV1; PEFR: peak
expiratory flow rate; RCT: randomised controlled trial; SABA: short-acting beta-agonists; SC: subcutaneous; SGRQ: St George’s
Respiratory Questionnaire.
Table 2. Lung function
Intervention Control
Study Outcome N Pre-dose
median
(IQR)
Post-dose
median
(IQR)
N Pre-dose
median
(IQR)
Post-dose
median
(IQR)
Median
difference
P value
(between
groups)
Flood-
Page 2003
FEV1 L/s 11 3.05
(2.69 to 3.
28)
3.1
(2.82 to3.
85)
13 3.1
(2.65 to 3.
51)
3.06
(2.65 to 3.
45)
0.15 0.22
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Table 2. Lung function (Continued)
Flood-
Page 2003
Morn-
ing PEFR
L/min
11 433
(402 to
497)
436
(417 to
503)
12 459.5
(408 to
481)
448
(370 to
490)
21 0.09
FEV1 : Forced expiratory volume in 1 second; IQR: interquartile range; PEFR: peak expiratory flow rate
Table 3. Eosinophils from Flood-Page 2003
Outcome Intervention Control P value
N Pre-dose
median
(IQR)
Post-dose
median
(IQR)
N Pre-dose
median (IQR)
Post-dose
median (IQR)
BALF (% cell
type on cy-
tospin)
Eosinophils
11 1.4
(0.9 to 10.2)
0.3
(0.01 to 0.8)
13 1.2
(0.2 to 6)
1.2
(0.3 to 1.6)
0.4
BALF: bronchoalveolar lavage fluid; IQR: interquartile range
Table 4. Eosinophils from Haldar 2009
Outcome Intervention Control
N Percentage N Percentage P value
Ge-
ometric mean spu-
tum eosinophil %
during exacerbation
29 1.5% 32 4.4% 0.005
Sputum eosinophil
count >3% during
exacerbation (% of
episodes)
29 36% 32 59% 0.04
Table 5. Sputum eosinophil results from Leckie 2000
Intervention
Mepolizumab
(10 mg/kg)
N=8
Intervention
Mepolizumab
(2.5 mg/kg)
N=7
Outcome Day Difference (95%CI) Difference
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Table 5. Sputum eosinophil results from Leckie 2000 (Continued)
Difference in blood eosinophils
vs placebo pre-allergen
Day − 14 0.08 (− 0.09 to 0.26), P = 0.4960 0.18 (0.01 to 0.36), P = 0.0292
Day 8 0.17 (0.04 to 0.30), P = 0.0054 0.01 (− 0.16 to 0.19), P = 1.00
Day 29 0.21 (0.10 to 0.33), P < 0.0001 0.02 (− 0.14 to 0.18), P = 1.00
Difference in blood eosinophils
vs placebo post-allergen
Day − 13 0.38 (0.07 to 0.69), P = 0.0144 0.23 (− 0.11 to 0.58), P = 0.2136
Day 9 0.34 (0.13 to 0.55), P = 0.0006 0.32 (0.11 to 0.53), P = 0.0012
Day 30 0.49 (0.28 to 0.7), P < 0.0001 0.43 (0.22 to 0.65), P = 0.0002
Difference in sputum
eosinophils vs placebo
Day -13 − 2.0 (− 16.2 to 12.3), P = 1.00 − 2.1 (− 16.3 to 12.2), P = 1.00
Day 9 11.3 (2.6 to 20.1), P = 0.0076 5.0 (− 5.9 to 16.0), P = 0.6108
Day 30 12.1 (3.1 to − 21.0), P = 0.0050 5.9 (− 5.0 to 16.8), P = 0.4454
Table 6. Sputum eosinophil results from Nair 2009
Outcome Visit Intervention Control P value
N median (range) N median (range)
Spu-
tum eosinophils
(%) median
Visit 1 9 16.6 (1.6 to 54.3) 11 4.0 (0 to 35.3) P < 0.05 compared to base-
line
4 weeks after first
dose
9 0 (range 0 to 4.0) 10 3.0 (0 to 16.3) P < 0.05 compared to base-
line
mean (SD) mean (SD)
Blood
eosinophils (x 10
9/L)
Visit 1 9 664.4 (492.5) 11 352.1 (± 253.7) P < 0.05 compared to base-
line
4 weeks after first
dose
9 49.5 (37.5) 10 295.8 (± 207.4) P < 0.05 compared to base-
line
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A P P E N D I C E S
Appendix 1. Sources and search methods for the Cochrane Airways Group Specialised Register
(CAGR)
Electronic searches: core databases
Database Frequency of search
CENTRAL (the Cochrane Library) Monthly
MEDLINE (Ovid) Weekly
EMBASE (Ovid) Weekly
PsycINFO (Ovid) Monthly
CINAHL (EBSCO) Monthly
AMED (EBSCO) Monthly
Hand-searches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
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MEDLINE search strategy used to identify trials for the CAGR
Asthma search
1. exp Asthma/
2. asthma$.mp.
3. (antiasthma$ or anti-asthma$).mp.
4. Respiratory Sounds/
5. wheez$.mp.
6. Bronchial Spasm/
7. bronchospas$.mp.
8. (bronch$ adj3 spasm$).mp.
9. bronchoconstrict$.mp.
10. exp Bronchoconstriction/
11. (bronch$ adj3 constrict$).mp.
12. Bronchial Hyperreactivity/
13. Respiratory Hypersensitivity/
14. ((bronchial$ or respiratory or airway$ or lung$) adj3 (hypersensitiv$ or hyperreactiv$ or allerg$ or insufficiency)).mp.
15. ((dust or mite$) adj3 (allerg$ or hypersensitiv$)).mp.
16. or/1-15
Filter to identify RCTs
1. exp “clinical trial [publication type]”/
2. (randomised or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. Animals/
10. Humans/
11. 9 not (9 and 10)
12. 8 not 11
The MEDLINE strategy and RCT filter are adapted to identify trials in other electronic databases.
Appendix 2. Search Strategy for Cochrane Airways Group Register
#1 AST:MISC1
#2 MeSH DESCRIPTOR Asthma Explode All
#3 asthma*:ti,ab
#4 #1 or #2 or #3
#5 MeSH DESCRIPTOR Antibodies, Monoclonal
#6 MeSH DESCRIPTOR Antibodies, Monoclonal, Humanized
#7 mepolizumab*
#8 SB24056 or SB-24056
#9 human* NEAR2 monoclonal* NEAR2 antibod*
#10 Bosatria
#11 #5 or #6 or #7 or #8 or #9 or #10
#12 #4 and #11
[In search line #1, MISC1 denotes the field where the reference has been coded for condition, in this case, asthma]
78Mepolizumab versus placebo for asthma (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
SM, KD, NW and CP contributed to the writing of the protocol. NW and CP independently selected trials for the review, NW and LB
extracted the data, and KD entered the data into the RevMan file with cross-checking by SM. KD and SM wrote the Results section,
and NW, LB, CP, KD and SM coauthored the Discussion and Conclusions.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research (SJM), UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
We initially planned to use a fixed-effect model for meta-analysis, but we agreed with a peer reviewer who suggested that a random-
effects model was more appropriate in view of the substantial clinical heterogeneity between the trials.
Although sufficient studies were not identified to conduct subgroup analyses, a posthoc subgroup analysis of dose of intervention was
identified and included for use in a future version of this review.
We have included lung function and asthma symptoms in the summary of findings table as additional outcomes which we believe to
be important to people making decisions about this intervention.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Antibodies, Monoclonal, Humanized [∗administration & dosage]; Asthma [∗therapy]; Disease Progression; Injections, Intravenous;
Injections, Subcutaneous; Quality of Life
MeSH check words
Adolescent; Adult; Child; Humans
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